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ABSTRACT 
The inhibitors of histone deacetylases (HDACs) have shown promising neuroprotective 
and neuroactive properties.  A set of pan- and isoform-specific HDAC inhibitors were evaluated 
for neurotrophic activity on Neuroscreen-1 (NS-1) cells, a subclone of PC-12 (rat 
pheochromocytoma) cells. 
The HDAC inhibitors were tested alone and in combination with nerve growth factor 
(NGF). An in vitro method has been standardized that measures neurite outgrowth along with 
cytotoxicity of test compounds in a single assay.  The neurotrophin signaling pathways were 
interrogated with selective inhibitors of MEK1/2 (PD98059/U0126) PI3K (LY294002) and TrkA 
(GW441756) and phosphorylation of target kinases.  Associated factors namely, acetylation of 
histones (H3/H4) and α-tubulin, role of cAMP, and cell- cycle analysis with flowcytometry were 
also studied. 
Vorinostat, a pan HDAC inhibitor, independently induced significant neurite outgrowth in 
NS-1 cells, similar to that of NGF.  The inhibitors of MEK1/2 & PI3K attenuated the NGF and 
vorinostat mediated neurite outgrowth.  Vorinostat induced phosphorylation of ERK1/2 was 
abolished in presence of U0126.  Both, vorinostat-mediated neurite outgrowth and activation of 
ERK were attenuated in presence of the TrkA inhibitor, GW441756, indicating the role of 
activation of upstream neurotrophin receptor.  Vorinostat produced hyperacetylation of α-tubulin 
and histones H3/H4. However, SQ22536 (the adenylate cyclase inhibitor) further stimulated 
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neurotrophic action of vorinostat.  Trichostatin A (TSA), belinostat and additional pan-HDAC 
inhibitors, showed variable effects.  TSA was ineffective, while belinostat attenuated neurotrophic 
action of NGF.  Belinostat though induced hyperacetylation of H3 & H4 but failed to produce 
acetylation of α-tubulin. PCI-34051, the HDAC 8 inhibitor, produced marginal neurotrophic action 
but did not produce hyperacetylation of H3/H4 and α-tubulin.  Tubastatin-A, the HDAC 6 
inhibitor, although produced hyperacetylation of α-tubulin but did not show any neurotrophic 
action.  Tenovin-1, a sirtuin inhibitor, attenuated neurotrophic action of NGF and did not produce 
hyperacetylation of H3/H4. 
These results suggest promising neurotrophic action of vorinostat via activation of MEK1/2 
& PI3K pathways involving activation of upstream TrkA, a neurotrophin receptor.  Bioactive small 
molecules with neurotrophic and neuritogenic actions, like vorinostat identified in present studies, 
hold great promise as therapeutic agents for treatment of neurodegenerative diseases and neuronal 
injuries by virtue of their ability to stimulate neuritic outgrowth. 
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CHAPTER 1 
INTRODUCTION 
1.1 Acetylome: Protein Lysine acetylation and Deacetylation functions 
Post-translational modifications are prominent, important and necessary processes for 
transformation of raw protein molecules into functional entities.  The acetylation of proteins at 
specific lysine residues by acetyltransferases enzymes has emerged as a biologically related 
regulatory modification like phosphorylation (Kouzarides, 2000). The acetyl transferases catalyze 
transfer of acetyl group from acetyl Co-A to the α-amino group of the amino terminal residues or 
to the ε-group of specific lysine residue (Allis et. al., 2007). Deacetylation, the reverse reaction of 
removal of acetyl group from acetyl lysine residues, is accomplished by another group of enzymes 
named deacetylases. Lysine protein acetylation was first identified in histones many years ago so 
many KATs and KDACs are often referred to as histone acetyl transferases (HATs) and 
deacetylases (HDACs) (Yang and Seto, 2008). A variety of proteins are known to be acetylated 
including histones and non-histone proteins. Lysine acetylation is known to occur in over 80 
transcription factors, a large number of nuclear regulators and several cytoplasmic proteins 
(Glozak et. al, 2005). Post translational modifications of these proteins play a very significant role 
in variety of cellular and biological process. Some of the prominent cellular process controlled by 
the lysine protein acetylation/deacetylation include chromatin modification and transcription, gene 
silencing, cellular differentiation, cell cycle progression, DNA replication, DNA repair 
(Chaudhary et. al., 2009) apoptosis (Lebel et. al., 2000). Most of the intermediate enzymes in the 
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metabolic pathways are acetylated. Acetylation of these enzymes regulates cellular metabolism by 
directly affecting their stability and functions (Zhou et. al., 2010). Lysine protein acetylation also 
plays important role in p53 functions and interaction and stabilization of microtubules.  
1.2 Histone acetylation and deacetylation 
Chromatin is the state in which DNA is packaged within the nucleus of the cell. The 
fundamental unit of the chromatin is the nucleosome, which is composed of octamers of the four 
core histones (H3, H4, H2A, and H2B). Each histone octamer is wrapped around with 147 base 
pairs of DNA (Kourzadias, 2007). Chromatin is a very active structure as it responds to various 
signals and controls functions of the DNA. Histone modifications are the main components that 
regulate DNA functions. Histones undergo a variety of post-translational modifications namely 
acetylation, phosphorylation, methylation and ubiquitination (Bannister and Kouzadias, 2011). 
Histone acetylation is one of the important post-translational modifications that regulate gene 
expression. Acetylation and deacetylation is a highly dynamic process and is catalyzed by interplay 
of two opposing enzymes histone acetyl transferases (HATs) and histone deacetylases (HDACs) 
(Figure 1.1).  HATs catalyze the addition of acetyl group at the lysine side chain of histones while 
HDACs catalyze removal of acetyl group from epsilon amino group of the lysine side chain of 
histone. Acetylation of histone tails neutralizes their positive charge resulting into loosening of 
histones and the associated DNA, thereby providing the relaxed chromatin structure that is 
accessible to the transcription factors and thus promoting transcriptional activation (Parthun 2007). 
Conversely, deacetylation of histone favors chromatin compaction.  Generally, hyperacetylation 
of histone is associated with transcriptional activation, whereas hypoacetylation is associated with 
transcriptional repression (Hsieh et. al., 2004).   
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Figure 1.1. Role of histone acetylation and deacetylation in process of transcription regulation. 
  
Adopted from Chuang et.al., 2009
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1.3. HAT and HDACS 
1.3.1. Histone Acetyl Transferases (HATs) 
In humans, there are about 30 known HATs, which have been grouped into five families 
based on structural and functional similarity of their catalytic domains.  Gcn5 related N-Acetyl 
transferases (GNATs) have derived their name from bearing similarity to yeast Gcn5 (general 
control nonderepressible-5) enzymes.  This group includes HAT Gcn5 and its relative and some 
distantly related HATs like Hat1, Elp3 and Hpa2. GNATs have four conserved motif (A-D) within 
the catalytic domain HAT domain.  Motif A is the most highly conserved and contains an Arg/Gln-
X-X-Gly-X-Gly/Ala sequence that is important for acetyl-CoA recognition and binding (Roth et. 
al., 2001).  The chromodomain or bromodomain in GNATs are involved in their binding with 
methylated and acetylated lysine respectively (Neuwald and Landsman, 1997).  The MYST 
families of HATs are originally named for their founding members MOZ, Ybf2, Sas2, and Tip60. 
The MYST HATs plays a very important role in posttranslational modification of histones. MYST 
HATs have a characteristic domain that contains acetyl CoA binding motif and a zinc finger motif 
(Avvakumov and Cote, 2007).  The other families are global co-activators nuclear receptor 
coactivators and divers.  The global co-activator includes p300 and CREB binding Protein. Nuclear 
receptor co -activators includes steroid receptor co-activator (SRC-1), ACTR, and (Transcriptional 
intermediary factors) TIF2.  The divers include TAFII 250 (TATA binding protein (TBP) - 
associated factor) and P160 (Sadoul et. al., 2011).   
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1.3.2. Histone Deacetylases (HDACs)   
Histone deacetylases are enzymes that remove acetyl group from histones leading to 
compact chromatin structures. HDACs are part of co-repressor complexes.  The HDACs have been 
shown to control many biological processes such as cellular proliferation, differentiation and 
development by binding to many transcription factors and transcription co-regulators (Haberland 
et. al., 2009). 
To date ,18 mammalian HDACs have been identified and divided into four major classes 
based upon their homology to yeast histone deacetylases (Figure 1.2) (de Ruijter et.al., 2003) 
HDACs 1, 2, 3 and 8 are grouped in Class I based on their homology to yeast transcriptional 
regulator, reduced potassium deficiency 3 (Rpd3).  The class I HDACs are predominantly localized 
in the nucleus. HDACs 1, 2 and 3 are expressed in the nucleus and have been shown to be involved 
in cell proliferation and death (Weich et. al., 2009). HDAC 8 is found to be expressed in smooth 
muscle where it is found to play important role in muscle contractility.  The class II deacetylases 
share homology with yeast Histone Deacetylase 1 (HD1) proteins and are further grouped into 
class IIa and Class IIb. The Class IIa includes HDACs 4, 5, 7 and 9, while Class IIb includes 
HDAC6 and 10.  The classes II HDACs have been found to shuttle between the nucleus and 
cytoplasm and seem to have a role in the tissue specific developmental activities (Bjerling et. al., 
2002).  Class IV includes only one atypical HDAC isoform 11.  It is highly expressed in the 
kidneys, testis and brain. HDAC11 is known to deacetylate histones as well as some non-histone 
proteins namely, a nuclear hormone receptor, transcription factors and cytoskeletal elements 
(Haberland et. al., 2009, Yang and Seto, 2008).  Class I, II and IV HDACs are zinc-dependent and 
are also called as classical HDACs. Class III HDACs, commonly known as sirtuins (SIRT 1-7), 
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are structurally and functionally different from the classical HDACs.  These NAD-dependent 
HDACs are similar to yeast SIR 2 (Silent Information Regulators 2) (Weich et. al., 2009).  Sirtuins 
are involved in regulation of metabolism, stress response and aging (Michan and D, 2007). 
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Figure 1.2. Classification of Histone Deacetylases (HDACs) and their cellular localization.  
Classification of HDACs and their localization 
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1.4. HDAC Inhibitors (HDACi) 
HDACi are small molecule natural or synthetic inhibitors of HDAC enzymes.  These 
compounds vary in structures, selectivity and biological activities.  HDACi pharmacophore is 
typically consisting of a metal-binding moiety or functional group, a capping group and a linker. 
The metal binding group coordinates to the catalytic metal atom within the HDAC active site.  The 
capping group interacts with the residues at the entrance of the active site and the linker is 
structurally related to the carbon chain present in the acetyl-lysine substrate.  Main function of the 
linker is to appropriately position the metal-binding moiety and capping group for interactions 
with the HDAC active site (Finnin et.al., 1999) (Figure1.3.A). HDACi have been grouped into 
four major classes, based on chemical nature of the inhibitor. (A) Hydroxamates (eg, Vorinostat 
(SAHA), Belinostat (PXD101), Panobinostat (LBH589) and Trichostatin A.  The hydroxamate 
HDACi are non-specific and show activity against class I and class II HDACs. Trichostatin A and 
vorinostat are pan-HDAC inhibitors of all zinc-dependent HDACs and are reported to cross blood 
brain barrier. (B)  The cyclic peptide HDACi includes depsipeptides and trapoxin. In in vitro 
assays, cyclic peptides are active at nanomolar concentrations (Marks, 2010) (C) The benzamide 
HDACi include entinostat (MS-275) and mocetinostat and (D) Short chain fatty acids HDACi 
include sodium butyrate and valproic acid (Marks, 2010)  (Table1.3.B).  The short chain fatty acids 
HDACi could also cross blood brain barrier, however they are relatively moderate HDACi (Bulter 
and Bates, 2006).  The majority of HDACi available are non-specific inhibitors of all the HDAC 
isoforms. These are generally referred as pan-HDAC inhibitors. TSA and vorinostat are example 
of canonical pan-HDAC inhibitors that inhibit HDACs 1-9 with equivalent potency. Selective 
HDACi can be classified into either class-specific (inhibiting several isoforms within a single 
class) or isoform-specific HDAC inhibitor (selectively inhibiting a specific HDAC isoform). 
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Selective HDAC inhibitors are important for determining the molecular mechanism of functions 
of a specific HDAC isoform.  Recently, significant attempts have been made towards development 
of selective HDAC inhibitors.  Tubacin, an HDAC inhibitor, selectively targets the HDAC6 and 
deacetylation of α-tubulin (Haggarty et. al., 2003).  Romidepsin (FK-228) is a cyclic tetrapeptide, 
which potentially inhibits HDAC 1 and 2 (Itoh et. al., 2008).  Apicidin, another cyclic tetrapeptide 
is a highly potent inhibitor of HDAC2 & 3 (Khan et. al., 2008) MS-275, a synthetic benzamide 
derivative, preferentially inhibits HDAC1 as compared to HDAC 2, 3 and 9. MS-275 exhibits little 
to no activity against HDAC4, 6, 7 and 9 (Khan et. al., 2008).  Suramin inhibits human NAD+ 
dependent class III SIRT 1 and SIRT 2 activity (Trapp et. al., 2007).  
Basic structure of HDAC inhibitors 
 
Figure 1.3. (A) Basic structure of HDAC inhibitors. 
A 
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Figure 1.3. (B) Classification of HDAC inhibitors based on their chemical structure.   
CLASSIFICATION OF HDAC INHIBITORS 
Class Compounds Structure 
Hydroxamates TSA 
(Trichostatin A) 
 
Cyclic 
peptides 
Entinostat  
Benzamides Trapoxin B  
Short chain 
fatty acids 
Valproic acid  
B 
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1.5. HDACi as potential therapeutic agents for treatment of neurological disorders 
Inhibition of HDAC activity with HDACi has attracted significant therapeutic attention. 
Earlier interests were mainly focused on development of HDACi as anticancer agents (Kazantsev 
and Thompson, 2008).  HDAC inhibitors, including butyrate, trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA), MS-275, and others, inhibit growth and induce 
differentiation in various cell culture models of cancer, including leukemia. SAHA (vorinostat, 
Zolinza) is the first HDACi approved by the FDA for cutaneous T- cell leukemia. A number of 
HDACi are currently in Phase I and Phase II clinical trials as cancer therapeutics (Marks and Xu, 
2009). More recently, the therapeutic interests in HDACi have broadened to non-malignant 
conditions affecting the nervous system (Kazantsev and Thompson, 2008).  Targeting HDACs 
with HDACi might be useful for treatment of neurological disorders such as amyotrophic lateral 
sclerosis, seizure disorders, Alzheimer's disease, Rubinstein-Taybi syndrome, spinal muscular 
atrophy, Rett syndrome, stroke, Fragile X syndrome, and Huntington's disease (Chuang et. al., 
2009).  The HDACi also seem promising for therapy related to several psychiatric disorders, 
including schizophrenia, depression, drug addiction, and anxiety disorders (Guidotti et. al., 2009). 
The levels and activities of HATs and HDACs are finely balanced in neuronal cells under normal 
conditions (Saha et. al., 2006).  In neurodegenerative disease, the histone acetylation homeostasis 
is greatly impaired, shifting towards hypoacetylation (Saha et. al., 2006).  The histone 
hyperacetylation produced by direct inhibition of HDACs leads to neuroprotective actions. 
Besides, inhibition of HDACs and histone hyperacetylation, the neuroprotective effect of HDACi 
may also involve multiple mechanisms of action, including activation of the extracellular signal 
regulated kinase pathway (Hao et. al., 2004), the inhibition of pro-apoptotic factors (Kim et. al., 
2007) or microglial–mediated inflammation (Peng et. al., 2005), as reported earlier for valproic 
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acid.  Therefore, HDACs represent attractive molecular targets for the treatment of several 
neurological and psychiatric diseases.  In preclinical treatment models, the HDACi have exhibited 
neuroprotective effects and stimulation of neurogenesis in traumatic brain injury and ischemia 
(Kim et. al., 2009), restoration of learning and memory in traumatic brain injury in 
neurodegenerative mice (Das et. al., 2009), enhanced neuronal differentiation and synaptic 
plasticity (Vecsey et. al., 2007) and exerted antidepressant-like effects (Schroeder et. al., 2007).  
Vorinostat significantly reduced IFN- λ induced neurotoxicity of human astrocytes (Hashioka et. 
al., 2012). 
1.5.1. Spinal Muscular Atrophy 
In spinal muscular atrophy (SMA) models, SAHA has been shown to improve motor 
abilities, by improving the number of motor neurons in the mice. SAHA treatment was shown to 
improve weight loss in SMA mice (Riessland et. al., 2010).  In another study, daily injection of 
TSA in SMA mice after the onset of disease lead to HDAC inhibition activated SMN2 gene 
expression and improved survival and motor pathology and attenuated weight loss (Avila et. al., 
2007). 
1.5.2. Huntington Disease 
HDAC inhibitors treatment in R6/2 Huntington disease (HD) mouse model showed 
improvement in Rotarod performance, which indicates improvement in motor impairment.  SAHA 
has been shown to cross the blood brain barrier and increase histone acetylation in the brain 
(Hockly et. al., 2003).  Ferrante et. al., (2003) reported that sodium butyrate treatment attenuated 
neurodegenerative phenotype and improved survival in R6/2 HD models.  Treatment with SAHA 
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and sodium butyrate has been shown to slow photoreceptor neurodegeneration and improves 
lethality in a Drosophila model of HD (Steffan et. al., 2001).  A defect in microtubule transport is 
also attributed to the neuronal toxicity observed in HD.  Vorinostat and TSA have been shown to 
increase vesicular transport of BDNF by inhibiting HDAC6 and thereby increasing the acetylation 
of α-tubulin at Lys 40.  Acetylation of α-tubulin at Lys 40 influences the binding and motility of 
kinesin-1 (Dompirre et. al., 2007). 
1.5.3. Parkinson’s Disease 
Parkinson’s disease is a neurodegenerative disorder characterized by loss of dopaminergic 
neurons in substantia niagra of the brain.  In a study with a mouse model of PD treated with 
dopaminergic toxin MPTP, administration of HDAC inhibitor phenyl butyrate significantly 
attenuated the depletion of dopamine and loss of  tyrosine hydroxylase, the dopamine biosynthetic 
enzyme, positive neurons (Gardian et. al., 2004).  Mutations in presynaptic α-synuclein are 
associated with familial forms of PD (Gasser, 2001).  The α-synuclein mediates neurotoxicity in 
the nucleus.  Targeting of α-synuclein to the nucleus promotes toxicity, whereas cytoplasmic 
sequestration is protective in both cell culture and transgenic Drosophila (Kontopoulos et. al., 
2006).  Toxicity of α-synuclein could be rescued by administration of HDAC inhibitors such as 
vorinostat and sodium butyrate in both cell culture and transgenic flies.  It was found that treatment 
with the HDACi lead to reduced neuronal death in response to α-synuclein (Kontopoulos et. al., 
2006).  
TSA treatment resulted in decreased survival and increased apoptosis in dopaminergic 
neuronal cells like N27, MN9D and human SH-SY5Y cells (Wang et. al., 2009).  This finding 
suggested that the effect of HDAC inhibitors might be complex.  In some instances the HDAC 
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inhibitors could play a role in pathogenesis of the neurodegenerative disease while in others these 
may act as potential therapeutics for neurodegenerative disease.  These contrasting effects of 
HDAC inhibitor may be attributed to varying epigenetic status, cell type and tissue specificity. 
HDAC inhibitors such as TSA and VPA, the pan-HDAC inhibitors of class I and class II are non-
specific.  Plausibly, this non-specificity might contribute to contradictory effects observed in 
different cell types (Wang et. al., 2009).  
Most of the earlier reports on HDACi were focused on their anticancer, antiproliferative 
and antiapoptotic properties.  Hyperacetylation was associated with an increase in expression of 
pro-apoptotic genes such as Bax and P21.  However, an increase in acetylation also promoted 
expression of anti-apoptotic or pro-survival genes like Bcl-2 and growth factors, which leads to 
protective effects in other cell types.  This might be one mechanism by which HDAC inhibitors 
seem to be protective in neurons and deadly in cancerous cell (Saha et. al., 2006). 
1.5.4. Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is an adult onset neurodegenerative disease 
characterized by progressive loss of motor neurons in the brain, brain stem and spinal cord 
resulting in generalized weakness, muscle atrophy and mortality (Rowland and Shneider, 2001).  
Familial form of ALS are due to gain of functional mutation in the gene encoding Cu/Zn 
superoxide dismutase1 (SOD1) an antioxidant enzyme (Rosen et.al., 1993).  As transcriptional 
regulation may be involved in the pathophysiology of ALS, role of HDAC inhibitors have been 
studied in transgenic ALS mouse models. Studies done by Ryu et. al., (2005) have shown that 
administration of 4-phenylbutryrate starting before or shortly after the onset of symptoms resulted 
in extended survival, improved pathological phenotype and reduction in clinical impairment.  VPA 
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injection in G86R SOD1 mutant mice significantly attenuated the death of motor neurons, 
maintained normal level of acetylation of histones and restored the loss of HAT CBP (Rouax et. 
al., 2007).  Co- treatment of 4-phenylbutyrate and AEOL10150 a catalytic antioxidant to ALS 
mice had a cumulative effect on survival time and there was reduction in the markers of oxidative 
damage in the lumbar spinal cord (Petri et. al., 2006). 
1.5.5. Alzheimer’s Disease 
Alzheimer’s Disease (AD) is characterized by progressive memory loss and personality 
changes eventually leading to dementia (Burns & Iliffe, 2009).  Accumulation of extracellular β-
amyloid (Aβ) and neurofibrillary tangles resulting from hyperphosphorylation of Tau protein are 
the neuropathological hallmark of AD.  Daily administration of 4-phenylbutyrate in Tg2576 AD 
model reversed spatial memory deficit by normalizing Tau hyperphosphorylation in the 
hippocampus.  However, the Aβ levels were not affected due to treatment with 4-phenylbutyrate 
(Ricobaraza et. al., 2009).  In another study, daily injection of low doses of valproic acid in Tg2576 
AD mice at early onset of 27 months, significantly reduced Aβ plaque number and improved 
memory deficit.  The mechanism of Aβ plaque reduction by valproic acid was due to inhibition of 
GSK-3β-mediated γ-secretase cleavage of APP (Qing et. al., 2008).  Treatment of 3xTg-AD mice 
with a class III HDAC inhibitor, nicotinamide, prohibited memory impairment and reduced Tau 
pathology without affecting Aβ production.  There was also a chronic but low level of increase in 
endogenous p25, which was associated with improved learning and memory (Green et. al., 2008). 
  
16 
 
1.5.6. Multiple Sclerosis 
Multiple Sclerosis (MS) is a devastating autoimmune disorder of CNS.  Recent studies 
have pointed towards the potential therapeutic role of HDACi in this disorder.  A study by Camelo 
et. al., (2005) on experimental autoimmune encephalomyelitis (EAE), a model of multiple 
sclerosis, demonstrated that neuropathology of mice with EAE was ameliorated by TSA treatment.  
The animals treated with TSA showed reduced spinal cord inflammatory infiltrates, demyelination 
and axonal loss.  Interestingly, TSA treatment also increased the number of motor neurons in the 
ventral horn, suggesting the potential application of TSA in neuroprotection.  TSA treatment  
increased expression of neuroprotective proteins such as estrogen receptor-α, insulin growth 
factor-2 (IGF-2), glutamate transporter EAAT2 and glutathione peroxidase, and decreased the 
expression of pro-apoptotic Bax, Bid, caspase-2 and apoptosis-inducing factor (Camelo et.al., 
2005). 
Axonal damage is also an important cause of neurodegeneration, where histone 
deacetylases play an important role.  A study with a specific wallerian degeneration mouse (WID) 
shows delayed wallerian degeneration due to increase in activity of NAD+ dependent histone 
deacetylase SIRT 1.  These mice had an increased expression of the enzyme that produces NAD+ 
leading to increased SIRT 1 activity.  Neuronal damage due to progressive degeneration after 
axonal transfection in this specific mouse was inhibited (Arkai et. al., 2004). 
1.6. Neuroprotective effects of HDACi 
VPA has been shown to reduce the retinal neuronal death by optic nerve crush (ONC). 
VPA up regulated levels of Bcl-2, BDNF and TrkB in the retina post-injury (Zhang et. al., 2012).  
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VPA and Sodium Butyrate (SB) treatment caused hyperacetylation of histone H3K14, attenuated 
histone H3K9 hypermethylation in the BDNF promoter and promoted transcriptional activity. 
These results suggest that VPA seemed to protect retinal ganglion cells (RGC) from ONC by 
inhibiting neuronal apoptosis, presumably, via the activation of BDNF-TrkB signaling and HDAC 
inhibition (Zhang et. al., 2012). 
BDNF gene expression has been associated with mood-stabilizing effects in the bipolar 
disorder (BD).  BDNF plays important role in promoting neuronal survival and synaptic plasticity 
and has been widely studied as a biomarker of illness activity in BD (Kuipers et. al., 2006).  Laura 
et. al., (2014) examined repeated exposure of D-amphetamine (AMPH) in a bipolar animal model 
and also investigated effect of sodium butyrate.  They found that repeated AMPH administration 
increased the HDAC activity in the prefrontal cortex (PFC) without altering BDNF protein or 
mRNA levels.  While, administration of sodium butyrate partially reversed the HDAC activity. 
HDACi have shown potential for therapeutic application for treatment of neurodegenerative and 
psychiatric disease owing to their neuroprotective and memory enhancing properties and increased 
expression of BDNF.  Koppel and Timmusk, (2013) have compared the effect of class I/IIb HDAC 
inhibitor SAHA, a class I selective HDAC inhibitor MS-275 and class II selective inhibitor on 
MC1568 and a HDAC6 selective inhibitor Tubacin on BDNF mRNA expression in rat primary 
neurons.  They also found that inhibition of class II HDACs lead to rapid up -regulation of BDNF 
mRNA levels, whereas class I HDAC inhibition created a distinctly delayed BDNF induction.  
Their finding suggests that class II HDAC inhibitors play important part in regulating transcription 
of BDNF and may have potential application for treatment of neurological disorders.  Hasan et. 
al., (2013) investigated the role of HDAC inhibitors in neuroprotection after ischemia.  Their study 
demonstrated that VPA and TSA treatment after oxygen and glucose deprivation led to re-
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oxygenation in rat cortical neurons, promoted neuronal regeneration and neuronal protection 
through up-regulation of BDNF expression.  There was also a significant increase in three synaptic 
markers namely PSD95, GAP 43 and synaptophysin in VPA and TSA treated rat cortical neurons. 
Chen et. al., (2006) have shown that VPA promoted dopaminergic neuron in midbrain neuron/glial 
culture by stimulating the release of neurotrophins like BDNF and GDNF. VPA pretreatment was 
also demonstrated to protect midbrain dopaminergic (DA) neurons from LPS or 1-methyl-4-
phenylpyridinium (MPP+)-induced neurotoxicity.  LPS treatment reduced the uptake capacity of 
DA by 45% and this reduction was strongly blocked by VPA pretreatment in a dose-dependent 
manner. Similarly treatment with MPP+ also reduced DA uptake by 70% and VPA significantly 
reduced the degeneration of DA neurons by MPP+ toxicity. 
A recent study by Lu et.al., (2013) with LB-205 (pan HDAC inhibitor) in acute traumatic 
brain injury rat model showed that LB-205 treatment increased the survival of central nervous 
system (CNS) cells after the injury by virtue of preservation of NGF expression and activation of 
tyrosine kinase A receptor (TrKA) pathway.  The neuroprotective mechanism of HDACi was 
linked with upregulation of expression of NGF, activation of TrkA phosphorylation, phospho-
protein kinase B (p-AKT), NFκB and B-cell lymphoma 2 (Bcl-2) cell survival factors, while the 
expression of p75 neurotrophin receptor (NTR), phospho-JNK, and Bcl-2-associated X protein 
apoptosis factors were down-regulated.  Wu et. al., (2013) studied the effect of VPA, TSA, 4-
phenyl butyric acid (4-PBA) and nicotinamide in astrocyte and dopamine neuron glial culture. 
TSA and VPA increased the GDNF and BDNF transcripts in astrocytes.  The neurotrophin 
transcript levels were increased due to increase in GDNF promoter activity leading to elevation in 
level of H3 acetylation. VPA, TSA, 4-PBA and nicotinamide protected dopamine neuron/glial 
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culture from MPTP and LPS toxicity.  Both 4-PBA and nicotinamide decreased the release of 
TNF-α and cell survivability in microglial culture stimulated with LPS (Wu et. al., 2013). 
Treatment of SH-SY 5Y cells with VPA, stimulated neurite outgrowth and cell survival by 
activating ERK pathway.  VPA treatment enhanced norepinephrine uptake and also induced 
expression of GAP-43 and Bcl-2, the genes controlled by ERK pathway (Yuan et. al., 2001). VPA 
have been shown to prolong the life span of cultured cortical neurons and promote neuronal growth 
(Hao et. al., 2004).  In vivo effects have also shown HDACi to be neuroprotective in chronic 
neurodegenerative diseases (Siebzehnrubl et. al., 2007).  Increased acetylation of histones and the 
transcription factors in neurons have been shown to protect from apoptosis in animal models of 
neurodegeneration and promote neuronal differentiation (Siebzehnrubl et. al., 2007).  TSA and 
VPA have been shown to promote differentiation of hippocampal neural progenitor cells (Hsieh 
et. al., 2004). HDACi like MS-275, M334 and SAHA increase neuronal differentiation and inhibit 
oligodendrocytes production in adult subventricular zone precursor cells (Siebzehnrubl et. al., 
2007).  Zhou et. al., (2011) have reported that SAHA and sodium butyrate blocks G1 to S cell 
cycle progression in the neurosphere formation of adult subventricular cells.  Pro-neural 
transcription factors such as Neurog1 and Neurod1 are up regulated. SAHA has also been found 
to be neuroprotective in dopaminergic neurons from midbrain primary culture by induction of 
neurotrophic factors from astroglia through induction of histone acetylation (Chen et. al., 2012). 
Jung et. al., (2008) have reported VPA to induce differentiation and reduce proliferation in rat 
cerebral cortex neural progenitor cells via the activation of ERK-P21 Cip/WAFI pathway. HDACi 
have also shown roles in directing neuronal, cardiomyocytic and hepatic lineage differentiations 
(Kretsovoli et. al., 2012). 
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SAHA treatment increased survival of dopaminergic neurons in mesencephalic neuronal 
culture, which was evident by increase in percentage of dopamine uptake (Chen et .al, 2012). The 
neuroprotective quality of SAHA was attributed to astroglia.  SAHA was also found to induce the 
release of neuronal survival factors from astroglia by increasing the release of neurotrophic factors 
GDNF and BDNF.  SAHA induced hyperacetylation of histones and also induced expression of 
GDNF and BDNF in mesencephalic neuronal culture (Chen et .al, 2012).  A study on effect of 
various HDAC inhibitors on survival of rat retinal ganglion cells (RGC) led to the finding that 
sodium butyrate and VPA delayed the spontaneous cell death in RGC. However, potent HDACi 
TSA did not had the same effect in these cells (Biermann et .al, 2011). 
1.7. HDACi in neuronal differentiation  
HDACi induce histone acetylation in diseased neurons and may restore transcriptional 
balance and hence delay or stop cell degeneration (Sterner and Berger, 2000).  The neurotrophic 
activities of HDACi may be epigenetically controlled by acetylation of histone as well as non-
histone proteins such as transcription factors (Sterner and Berger, 2000).  The regulation of 
transcription by epigenetic modifications has been proven to be significant for neurite outgrowth 
and neuroprotection in the peripheral nervous system during neuronal development. An increase 
in acetylation of histones and transcription factors in neurons has been shown to promote 
differentiation of neurons and neurite outgrowth (Gaub et. al., 2010). TSA has been shown to 
produce differentiation of retinal ganglion Cells (RGC-5 cells).  The differentiation of RGC-5 cells 
induced by TSA was transcription dependent, as the neurite outgrowth was blocked in presence of 
a RNA polymerase inhibitor alpha amanitin (Schwechter et. al., 2007).  The differentiation of 
RGC-5 cells with HDAC inhibitors might be due to removal of neuron gene-specific transcription 
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repressor neuron restrictive silencing factor (NRSF) from NRSE. This process is critical though 
not necessarily adequate component of in vivo neuronal differentiation (Schwechter et. al., 2007). 
Tomioka et. al., (2014) have shown that TSA induced neurite outgrowth in PC12 cells  by  
expression of nur77, which was up-regulated due to acetylation of Lys 14 on histone H3.  Wang 
et. al., (2014) have shown that TSA increased the expression of neurotrophic factors in the Schwan 
cells (SC) and inhibited the expression of genes associated with myelin production. TSA was 
shown to play an important role in the growth and biological functions such as survival, 
proliferation, migration and myelination of SCs (Wang et. al., 2014). 
In cultured cortical granule neuron (CGN), hyperacetylation stimulates neuronal outgrowth 
and growth cone remodeling through inhibition of HDAC I and HDAC II by a transcription-
dependent mechanism.  It was found that TSA induced significant increase in expression of HATs 
such as CBP, p300 and P/CAF in cultured CGN.  Acetylation dependent –p53 signaling are also 
important events in allowing physiological pro-outgrowth signal in primary neuron (Gaub et.al, 
2010). 
Transcriptional control, chromatin remodeling and epigenetic modifications regulates the 
self-renewal and differentiation of neuronal stem cells (NSC) (Temple, 2001). During the 
development of the central nervous system in vertebrates, the fate of NSC is firmly controlled 
under temporal and regional manners and is also regulated by epigenetic controls (Temple, 2001). 
Reports have indicated that the HDACs play important role in controlling proliferation and 
differentiation of neural stem cells (Sun et. al., 2011).  HDAC1, 3, 5, and 7 are expressed in neural 
stem cells.  However, the expression of these HDACs is significantly reduced upon differentiation 
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(Sun et. al., 2007).  HDAC2 is expressed in proliferating neural stem cells and its expression is up 
regulated as neurons differentiate (Macdonald and Roskamas, 2008).  
A study on the effect of TSA on multipotent neural stem cells, that have the ability for self 
renewal and differentiation into neurons astrocytes and oligodendrocytes, demonstrated that TSA 
dose dependently, promoted neurite outgrowth in multipotent neural stem cells by significantly 
increasing branching points and dendritic area.  However, TSA inhibited the differentiation of 
NSC into astrocytes.  TSA also mediated cholinergic differentiation of NSC as evident by a 10% 
increase in cholinergic neurons after TSA treatment (Balasubramaniam et. al., 2006).  HDAC 
inhibitors have also been shown to increase neuronal differentiation of embryonic mouse neural 
stem cells (Siebzehnrubl et. al., 2007).  VPA treatment, at the progenitor stage of hippocampal 
treatment, led to strong inhibition of cell proliferation and induction of neuronal differentiation 
due to an increase in expression of proneural transcription factor.  The treatment with HDACi, 
increased expression of Ngn, Math1 and P15 and shifted the cells towards neuronal fate.  Also, the 
increased expression of proneural transcription factor was linked to acetylation of histone H4 (Yu 
et. al., 2009). 
Similar to neural stem cells, the pluripotent stem cells have also shown potential for the 
treatment of neurodegenerative disease owing to their capability to self-renew and differentiate 
into all cell types (Thomson et. al., 1998). Pluripotent stem cells (iPSCs) are very similar to 
embryonic stem cells and are produced from epigenetic reprogramming of somatic cells through 
the exogenous expression of four pluripotency-related transcription factors (Hochedlinger and 
Plath, 2009).  HDAC inhibitors have been shown to improve the efficiency of reprogramming of 
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somatic cells into pluripotent cells (iPSC). HDACi like, SAHA, TSA and VPA have shown 
important role in reprogramming of mouse embryonic fibroblast to iPSCs. (Huangfu et. al., 2008). 
HDAC inhibitors have also been shown to play important role in survival, proliferation and 
differentiation of rat neural precursor cells (NPC).  TSA treatment of NPC derived from Sprague 
Dawley rats E14.5 brain have shown decreased proliferation and increased differentiation of 
neurons along with decreased differentiation of astrocytes. Increased neuronal differentiation and 
proliferation of NPC was attributed to reduction in transcription of class II HDAC, while the 
transcription of class I HDAC was not changed (Liu et. al., 2012).  Hisahara et.al., (2008) have 
reported important role of SIRT1, a NAD+ dependent class III HDAC in the differentiation of 
NPC.  The SIRT1 was found predominantly in cytoplasm.  However when cultured NPCs were 
transferred to differentiation conditions, SIRT1 was expressed in the nucleus.  This implicated 
modulation of neuronal differentiation by SIRT1 nuclear translocation.  SIRT1 plays an important 
role in neuronal differentiation as evident by decrease in neuronal differentiation by inhibition of 
SIRT 1 by sirtinol, a SIRT1 inhibitor as well as use of siRNA against SIRT1. Over expression of 
SIRT1 promoted neuronal differentiation (Hisahara et. al., 2008).  
VPA induces neuronal differentiation in adult hippocampal neural progenitor cells (Hsieh 
et. al, 2004).  VPA treatment increases the level of acetylated histones.  The level of acetylated 
histones was higher in the neuronal cells as compared to astrocytes and oligodendrocytes. The 
acetylation of histones plays an important role in the differentiation of adult hippocampal 
progenitor cells; however deacetylation of histones or deacetylase activity plays an important role 
in differentiation of oligodendrocytes and astrocytes.  The VPA mediated neuronal differentiation 
of neural progenitor cells was linked to up-regulation of a neuron specific gene NeuroD, a bHLH 
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transcription factor (Hsieh et. al., 2004).  In another study, VPA produced differentiation of 
cortical neurons by activation of ERK Pathway.  Valproate induced phosphorylation of P44/42 
ERK were MEK and REF dependent, which was similar to action of neurotrophins (Hao et. al., 
2004).  VPA treatment in rat cerebral cortex  induced differentiation and reduced proliferation of  
neural progenitor cells via activation of ERK-P21 Cip/WAFI pathway mediated by β-catenin 
pathway (Jung et. al,. 2008). 
Husstege et. al., (2002) developed two models to investigate the role of histone 
deacetylation in oligodendrocyte differentiation.  Histone deacetylation has also been shown to be 
important for oligodendrocyte differentiation.  Deacetylation and subsequent methylation of 
histones promoted the differentiation of neural stem cells into neurons and glial cells.  The HDAC 
activity was necessary for oligodendrocyte differentiation from rat cortical progenitor cells 
(Husstege et. al., 2002).  
Investigation on the effect of VPA on neuronal differentiation with human bone marrow-
mesenchymal stromal cells (hBM-MSCs) showed that VPA treated MSCs differentiated on 
neuronal media and have shown increase in number/length of neurites as compared to 
differentiated MSCs.  The VPA treated MSCs exhibited cell morphology similar to neurons.  There 
was a significant increase in expression of neuronal marker such as Nestin, Musashi, CD133, and 
GFAP (Jeonga et. al., 2013). 
Sodium butyrate promoted neuronal differentiation of medulloblastoma (MB) cells, the 
malignant brain tumors of childhood.  Sodium butyrate increased the expression of Gria2 a 
neuronal differentiation marker in human medulloblastoma cell lines, D283 and DAOY. HDAC 
inhibitors have shown to reduce the MB stem cells survival and proliferation (Nor et. al., 2013). 
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VPA specifically enhanced neuronal differentiation in human FGF1 gene 1B promoter (-
540 to +31) driven green fluorescence F1BGFP (+) embryonic stem cells and Neural 
stem/progenitor cells (NSPCs) rather than GFP(-) cells (Kao et. al., 2013).  NSPCs were the major 
cell population responsive for VPA-induced neuronal differentiation than GFP(-) cells.  VPA 
activates human FGF1 gene promoter through inhibition of HDAC and GSK-3 activities. 
Her et. al., (2010) have shown that HDAC inhibitors  namely, TSA, sodium butyrate and 
VPA, promote differentiation of rat C6 glioma cells through production of neuroactive 5α-reduce 
neurosteroid, which stimulated expression of serotonin stimulated brain derived neurotrophic 
factor  transcription.  These HDACi also stimulated production of glial fibrillary acid (GFAP). 
Niemann–Pick type C disease (NPC) is a neurodegenerative associated with lipid storage 
disorder (Liscum and Klansek, 1998).  In NPC1-/-, mice self-renewal and differentiation of neural 
stem cells (NSC) are impaired.  Treatment of NPC1-/- mice with VPA enhanced neuronal 
differentiation and restored impaired astrocytes in NSCs from NPC1−/− mice.  There was an up-
regulation of essential neurotrophic genes (TrkB, BDNF, MnSoD, and NeuroD), through 
repression of the REST/NRSF and HDAC complex by the VPA treatment.  Up-regulation of 
neurotrophic genes enhanced neural differentiation and cholesterol homeostasis in neural stem 
cells from NPC1−/− mice (Kim et, al., 2007). 
HDAC1 has also been shown to have an important role in regulating the switch between 
proliferation and differentiation in retina of zebra fish.  The ratio of the number of differentiating 
cells to that of proliferating cells was increased in proportion to HDAC activity due to treatment 
of zebrafish with TSA, which suggests that HDAC might regulate the crucial step of retinal 
neurogenesis in zebrafish (Yamaguchi et. al., 2003).  
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1.8. Importance of neuronal differentiation/ neuritogenesis/ neuroregeneration 
Neuroregeneration is a new notion that includes neuroplasticity, neurogenesis and 
neurorestoration (Enciu et. al., 2011).  Earlier it was believed that nerve regeneration in the 
mammalian central nervous system (CNS) was irreversible, but recent reports have suggested that 
damaged neurons do regenerate in an active process under the presence of stimulatory substances 
such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) (Brinton et.al., 
1998; Filbin, 2000; Fournier and Strittmatter, 2011; McKerracher; 2001 and Pesavento, et. al., 
2002).  Neurite outgrowth, an important cellular process for neurogenesis, is a complex process 
that involves three stages (1) sprouting; the initiation of neurite formation, (2) elongation of axon 
and (3) branching of dendrites followed by formation of synapses (Kiryushko et. al., 2004).  
Neuritogenesis is a primary cellular differentiation process for formation of new neurons.  
Understanding the cellular and molecular mechanisms of this process is important, because 
neuritogenesis is required for proper wiring of the brain and nerve regeneration, and has been 
associated with various neurodegenerative diseases (Jones et. al., 2001).  Recent reports have 
emphasized the significance of neurite outgrowth in the process of neuroregeneration and repair 
of damaged neurons (Maruoka et. al., 2011).  The physiological substances, which trigger the 
process of neuritogenesis, are commonly referred as neurotrophic factors.  Neurotrophic factors 
are proteinacious growth factors that promote neuritic outgrowth, repair damaged neurons and may 
play a significant role in restoration and readjustment of normal neuronal functions of the damaged 
neurons (Li et. al., 2002).  These factors are produced and released by the target neuronal tissues 
and initiate the growth and differentiation of developing neurons.  The nerve growth factor (NGF), 
brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophic factor-4/5 
(NT-4/5) are commonly referred as neurotrophins. 
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Use of natural neurotrophins seems to be an obvious choice in the process of neuronal 
regeneration. However, despite their undeniable positive effects, therapeutic applications of 
natural neurotrophins like NGF and BDNF, for treatment of neurodegenerative diseases, are 
limited due to their negligible entry through the blood brain barrier and also susceptibility to 
degradation by peripheral peptidases (Maruoka et. al., 2011).  Recently, there has been significant 
surge in identification of small molecular weight neurotrophic compounds, which can promote 
growth, differentiation, survival of developing and damaged neurons. 
There has been a great deal of research done on using neurotrophins as a possible therapy 
for people suffering from disorders involving neuronal degeneration and physical trauma resulting 
in the severing of nerve connections.  They can help direct and facilitate the survival of neurons 
after physical injury (i.e., motorcycle accidents and sports-related injuries) or in neurodegenerative 
diseases such as Alzhiemer's, Huntington's, and Parkinson's disease.  By applying these growth 
factors, primarily in the central nervous system area where neurons have more difficulty in 
repairing themselves (in comparison to the better repair capabilities of the Peripheral Nervous 
System), researchers today hope to make neurotrophins a more widely accepted clinical possibility 
in the field of neuroregeneration. 
Recent reports indicates neuroprotective and neurotrophic properties of small molecular 
weight inhibitors of histone deacetylases (HDACs) and their potential use in treatment of 
neurological disorders (Camelo et. al., 2005; Wiech et. al., 2009 and Xu et. al., 2011).  HDAC 
inhibitors by chromatin modification and epigenetic regulation may contribute to unique neuronal 
adaptations such as transcription-dependent neuroplasticity and learning (Kandel, 2001 and Wu 
et. al., 2007) or axon and dendrite regeneration. 
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1.9. Concluding Remarks: identification of small molecule neurotropic factors as potential 
therapeutic agents for treatment of neurodegenerative diseases 
The review of literature presented above describes the current status of the knowledge 
about role of various HDAC inhibitors in neuronal differentiation and neuroprotection in different 
cell lines and in vivo models.  Therapeutic application of several HDAC inhibitors for 
neurodegenerative diseases has also been discussed.  As evident by the literature survey, HDAC 
inhibitors have significant therapeutic potential for many of the neurodegenerative diseases such 
as PD, AD, SMN, ALS, TBI, MS and HD.  HDAC inhibitors brings about neuronal differentiation 
in neural stem cells (NSC), neural progenitor cells (NPCs), rat retinal ganglion cells (RGCs), 
dopaminergic neurons, SHSY5Y neuroblastoma cells, cortical granule neurons (CGN) and cell 
line such as PC12 cells.  HDAC inhibitors also possess neuroprotective and neurotrophic potential.  
However, potential limitations regarding safety of these HDAC inhibitors cannot be ignored.  
Reports indicate that HDAC inhibitors in some instances could play a role in pathogenesis of the 
neurodegenerative disease, while in others could act as potential therapeutics for the 
neurodegenerative disease.  These opposing effects of HDAC inhibitors could be attributed to 
varying epigenetic status of the targets, cell type and tissue specificity.  On occasion, the HDAC 
inhibitors have been shown highly neurotoxic rather than being neuroprotective.  The major 
problem associated with HDAC inhibitors is their lack of specificity and in particular their lack of 
isoform selectivity.  Another issue is incomple knowledge about non-target actions.  There is a 
great surge for learning about mechanism of action and the various ways that HDAC inhibitors 
affect gene expression.  Future research is expected to elucidate the mechanism of HDACi action 
in order to design novel reagents with increased effectiveness and specificity.  Research on 
specific/selective HDAC inhibitors would be beneficial from therapeutic point of view and would 
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likely overcome the problems currently associated with HDAC inhibitors.  Hopefully the rapid 
interest in the study of HDAC inhibitors will shed some light on the mechanism of action of these 
inhibitors and give us direction to combat neurodegenerative diseases. 
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1.10. Objectives of the study 
Neurite outgrowth is an intricate process that involves three stages (1) sprouting, the 
initiation of neurite formation (2) elongation of axon and (3) branching of dendrites followed by 
formation of synapses (Kiryushko et. al., 2004).  Neuritogenesis is a fundamental cellular 
differentiation process for formation of new neurons.  Understanding this process is important, 
because it is required for proper wiring of the brain and nerve regeneration, and has been associated 
with various neurodegenerative diseases (Jones et. al., 2001).  Reports indicate the significance of 
neurite outgrowth in the process of neuroregeneration and repair of damaged neurons. 
Neurotrophic substances that promote neuritic outgrowth can repair damaged neurons and may 
play a significant role in restoration and readjustment of normal neuronal functions of the damaged 
neurons (Li et. al, 2002).  The use of natural neurotrophic seems to be the obvious choice in the 
process of neuronal regeneration.  However, despite their undeniable positive effects, therapeutic 
applications of natural neurotrophins like NGF and BDNF are limited due to their negligible entry 
through the blood brain barrier and also destabilization by peripheral peptidases (Maruoka et. al., 
2011).  Bioactive small molecules with neurotrophic and neuritogenic actions may have promising 
use as therapeutic agents for treatment of neurodegenerative diseases and neuronal injuries by 
virtue of their abilities to stimulate neuritic outgrowth. Studies to identify low molecular weight 
compounds that can mimic the function of neurotrophic factors and substitute for their clinical use 
are in progress now.  The HDAC inhibitors may provide potential new neutrophic drug leads. 
Being, low molecular weight compounds, many of the HDACi have the ability to cross blood brain 
barrier.  HDACi play significant role in neuronal differentiation, neuroprotection, neurite 
outgrowth and in treatment of several neurodegenerative diseases as detailed in the preceeding 
review of literature.  In most cases molecular mechanisms of HDACi that were associated with 
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neuronal protection and differentiation were attributed to the induction of differentiation by 
regulation of the transcription factors and transcription.  However, further studies are needed to 
explain the mechanism of HDACi actions in order to design novel reagents with increased 
effectiveness and specificity (Kretsovali et. al., 2012).  Present studies aim to identify selective, 
pan and isoform specifics HDAC inhibitors with neurotrophic potentials i.e. ability of the HDACi 
to induce neurite outgrowth in vitro in appropriate cell lines and understanding the molecular and 
cellular mechanisms of their action.  
We have used Neuroscreen-1 (NS-1) cell line, a subclone of PC12 cells, as a model for 
studying the effect of HDACi on neurite outgrowth.  Pheochromocytoma (PC12) cell-line, clonal 
cells originated from a transplantable rat pheochromocytoma, is a widely used in-vitro model to 
study neuronal differentiation.  PC12 cells have important feature, when treated with NGF, they 
undergo a dramatic change in phenotype and acquire a number of characteristic properties of 
sympathetic neurons.  NGF-treated PC12 cells stop proliferation and start differentiation by 
extending neuritis and become electrically excitable (Westerink and Ewing, 2008).  However, in 
spite of their wide use, PC12 cells have some limitations.  Although the PC12 cells can acquire 
properties similar to sympathetic neuron, they lack development of definitive axons or dendrites 
and do not form true synapses with each other.  Additionally, the PC12 cells also have the potential 
for genetic drift with respect to repeated cell passage with a concomitant change in phenotype 
(Banker and Goslin, 1998).  NS-1 cell line shows improved adherence, shorter doubling time and 
higher responsiveness to NGF than parent PC12 cell culture (Dijkmanas et. al., 2008).  
Considering the critical issues mentioned above, we selected NS-1 cell line as a cellular models 
for the investigations related to in vitro neuritogenesis/neurite outgrowth.  Present study aims to 
identify selective, pan and isoform specifics HDAC inhibitors with neurotrophic potentials i.e their 
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ability to induce neurite outgrowth in Neuroscreen-1 cell and understanding the molecular and 
cellular mechanisms of their action. The specific aims of this study are outlines below :- 
Aim 1: Screen pan and selective HDAC inhibitors for neurotrophic potential and induction of 
neuritogenesis in NS-1 cells  
Aim 2: To investigate cellular and molecular mechanism of neurotrophic HDAC inhibitors  
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CHAPTER 2 
EXPERIMENTAL METHODS 
2.1. Cell culture 
PC12 is a widely used cell line, which was originally derived from a pheochromocytoma 
of the rat adrenal medulla (Giordano and Costa, 2011).  PC12 cells display an important feature, 
in that when treated with NGF, they undergo a dramatic change in phenotype and acquire number 
of characteristic properties of sympathetic neurons.  Additionally, the ease of maintaining and 
growing these cells in vitro and their characteristic pharmacological responses have allowed the 
application of PC12 cells as a standard model system for neurons (Green and Tischler, 1982).  The 
treatment of PC12 cells with NGF stops proliferation and starts their differentiation by extending 
neurites, which are electrically excitable (Green and Tischler, 1982). 
Neuroscreen-1 (NS-1) cells were procured from Cellomics (Pittsburg, PA, USA). NS-1 
cells, a sub-clone derived from the PC12 cell culture, display several substantial advantages over 
PC12 cells, including faster growth, no aggregation and better responsiveness to NGF (Dijkmans 
et. al., 2008). NS-1 cells were cultured in RPMI 1640 medium containing 10% horse serum, 5% 
fetal bovine serum, 2mM L-glutamine, 100 units/mL penicillin and 100µg/ml streptomycin and 
incubated at 37ºC, in a 5% CO2 and 95% humidified incubator.  The NS-1 cells were sub-cultured 
after 2-3 days or twice a week for maintaining culture.   
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2.2. In vitro cytotoxicity & neuritogenesis assay 
2.2.1. Cell Differentiation 
NS-1 cells were seeded onto a collagen IV coated clear 96 well plate (BD Biosciences) 
with 2000 cells/well.  The cells in RPMI-1640 growth medium were allowed to adhere onto the 
plate surface for 24 hours.  The cultures were treated with specified concentrations of HDAC 
inhibitors, NGF and other signaling inhibitors as specified for 48 hours. 
2.2.2. Cell Viability/Cytotoxicity Assay  
Cell viability/cytotoxicity was determined using alamarBlue colorimetric quantitative 
method. This method uses a resazurin reduction assay.  In physiologically active cells resazurin is 
reduced to resorfurin giving a bright red fluorescence.  After 48 hours of treatment with test 
compounds and/or NGF, 10µl of the alamarBlue reagent was added directly to the media in each 
well. Plates were further incubated overnight.  The fluorescence was measured at 544nm excitation 
and 590nm emission and the data were analyzed to determine viability/cytotoxicity. 
2.2.3. Staining and Images: 
After reading the plates for cell viability, plates were washed with phosphate buffered 
saline (PBS), fixed with methanol and stained with Giemsa for 1 hour.  The plate was then washed 
with distilled water, dried under air and subjected to digital imaging under a bright light 
microscope for measurement of neuritogenesis.  At least three images were captured from each 
well, and analyzed by NIS element software for quantification of neuritogenesis.  Representative 
photomicrographs were captured with a Nikon digital camera attached to the microscope.  From 
each well, multiple fields per well were selected manually and images were captured.  The images 
were captured using 10X objective and the images were stored as JPEG files. 
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2.2.4. Analysis of NS-1 cells’ digital images for neurite outgrowth  
For each treatment, at least 50 cells were analyzed from the images captured from each 
well in triplicate.  Neurite length was calculated by tracing the neurites in each cell by computer 
mouse using Nikon NIS element software (Figure 2.1).  Mean neurite length and number of 
neurites were calculated from a known number of cells counted.  The data obtained was exported 
to an MS Excel file.  The values from the MS Excel file were copied and pasted into a macro-
based MS Excel template, which was designed to measure neurite outgrowth.  The neuritogenesis 
was assessed according to the following parameters: (a) mean neurite length (ratio between sum 
of length of total neurites measured to the number of neurites measured); (b) neurite length/cell 
(ratio between sum of length of total neurites measured to the number of cells counted); (c) 
neurites/cell (total number of neurites/ number of cells counted). 
 
[A]       [B]         [C] 
Figure 2.1. Measurement of neurite out growth in NS-1 cells by analysis of digital cell images with 
NIS element software. [A] Untreated cells [B] Cell treated with NGF and [C] An enlarged digital 
image showing neurites and neuritic nodes.  
To evaluate the signaling pathways involved in vorinostat induced neuritogenesis, cell 
cultures were pretreated with MEK1/2 inhibitors (PD98059 and U0126) (10 µM), PI3K inhibitor 
(LY294002) (10 µM), Trk inhibitor (GW441756) (1 µM) or the adenylate cyclase inhibitor 
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(SQ22536) (200 µM) as specified in more details in results, followed by treatment with vorinostat 
(1 µM) and/or NGF (2.5 ng/ml) (positive control) for an additional 72 hrs.  DMSO was used as 
the negative control in each assay.  Cytotoxicity and neurite outgrowth assays were also performed 
as described above.  
2.3. Analysis of phosphorylation of ERK1/2 by Western blotting 
NS-1 cells (2.5 X 105 cells/mL) were seeded onto collagen coated 25 cm² cell culture flasks 
and allowed to adhere for 24 hrs.  At least two 25 cm² cell culture flasks were set up for each 
treatment. Cells were treated with vorinostat (1 & 2.5 µM) and NGF (2.5 ng/mL) with and without 
U0126 for 5, 15, 30, 60 and 120 minutes.  Two control flasks were set-up for DMSO for each set 
of assay.  The culture medium was aspirated from the treated flasks and the cells were washed 
with ice cold 1X PBS. Lysis of cells was done with the 1X cell lysis buffer (20mM Tris HCL pH 
(7.5), 150mM NaCl, 1mM Na2 EDTA, 1mM EGTA, 1% Triton, 2.5mM sodium pyrophosphate, 
1Mm β-glycerophosphate, 1mM Na3V04, 1μg/mL leupeptin).  Cells were treated with 100 µl of 
1X cell lysis buffer per well for 6-well plate. Immediately after the lysis, the cells were scraped 
off the plate and the cell lysates were transferred to 1.5 mL micro-centrifuge tubes.  The tubes with 
the cell lysates were kept on ice till further treatment.  The cell lysates were sonicated by 
sonicator/cell disruptor model W-10 from Health System Ultrasonics for 10–15 secs for 3 times to 
complete cell lysis and shear DNA (to reduce sample viscosity).  The extract was spun in a cold 
microcentrifuge at 14,000xg for 10 min. The supernatant was removed for further use.  An equal 
volume of 2X SDS sample buffer (4%SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromophenol blue and 0.125 M Tris Hcl) was added to the cell lysates.  The samples were heated 
to 95–100°C for 5 min and further cooled on ice.  The protein contents in each lysate was estimated 
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with Bradford assay using Quick startTM Bradford 1x dye and following the standard protocol 
provided in the user manual. 
The 20 μg of samples were loaded onto 10% (10 cm x 10 cm) SDS-PAGE mini gels (Bio-
Rad, USA).  The electrophoresis was done at 200 V for 40 minutes.  The proteins from SDS-PAGE 
gel were electro-transferred to nitrocellulose membrane using Bio-Rad –Transblot Turbo transfer 
system.  The transfer was done at 1.3A-2.5 V for 7 minute using Bio-RAD protocol.  After transfer, 
nitrocellulose membranes were washed with 25 mL 1X Tris buffered saline (TBS) for 5 min at 
room temperature.  The membranes were incubated in 25 mL of blocking buffer (5% nonfat dried 
milk in 1x TBST [20 mM Tris–HCl (pH 7.5), 137 mM NaCl and 0.01% (v ⁄ v) Tween 20] for 1 hr 
at room temperature.  After the incubation, the membranes ware washed three times (for 5 min 
each) with 15 mL of TBST.  The membranes were further incubated overnight at 4°C with the 
primary antibody (at 1:1000 dilution) in 10 mL primary antibody dilution buffer (1X TBST with 
5% BSA) with gentle agitation.  The membranes were probed overnight with phospho-
p44/p42MAPK (ERK1/2) antibody (Cell Signaling Technology, USA) for measuring 
phosphorylated ERK1/2 and p44 MAPK (ERK1) antibody (Cell Signaling Technology, USA) for 
total ERK levels, following the manufacturer’s protocols.  The membranes treated with the primary 
antibody were washed three times (for 5 min each time) with 15 mL of TBST and incubated further 
with the anti–rabbit HRP-conjugated secondary antibody  (1:2000 dilution in 10 mL blocking 
buffer) with gentle agitation for 1 hr at room temperature.  Each membrane was developed with 
enhanced chemiluminescence (ECL) kit (GE Healthcare), following the manufacturer’s protocol.  
The images were captured, processed and analyzed on a Bio-Rad ChemiDoC MP imaging system.  
For analysis of acetylated histones H3 and H4 and acetylated α-tubulin, the cell lysates were 
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probed with antibodies against acetyl-histone H3 (Lys 9) and acetyl-Histone H4 (Lys 8) and acetyl 
α-tubulin (Lys 40). 
2.4. Immunolocalization of acetylated α-tubulin in NS-1 cells  
The NS-1 cells were seeded onto ibidi microchamber collagen IV coated 4 well plastic 
micro slides (1X10⁵ cells/well in RPMI1640 medium).  The cells were allowed to adhere for 24 
hrs. The cells were treated with vorinostat (1 and 2.5 µM) or 2.5 ng/mL NGF for 6 hours.  The 
culture medium was aspirated and the cells were fixed by adding 400 µl of 4% paraformaldehyde 
diluted in warm PBS for 15 min at room temperature.  After fixative was aspirated the chambers 
were rinsed three times with 1X PBS and slides were processed further for immunostaining. 
2.5. Immunostaining 
The cells were treated with the blocking buffer (1X PBS/5% normal serum/0.3% Triton™ 
X-100) for 60 minutes, followed by treatment with primary antibody-α-Tubulin (Lys40) (D20G3) 
XP® (1:800 dilution) overnight at 4 °C. Slides were rinsed three times with 1XPBS for 5 min each.  
The slides were incubated for 1 to 2 hrs at room temperature in the dark, with the secondary 
antibody (Anti rabbit IgG (H+L), F(ab')2  Fragment, Alexa Fluor 488 Conjugated) (Cell Signaling 
Technology) diluted 1:1000 in antibody dilution buffer (1X PBS/1% BSA/0.3% Triton™ X-100). 
The slides were rinsed 3 times with 1XPBS and treated with 300 μl of diluted DyLight™ 554 
Phalloidin (an actin staining dye) for 15 mins at room temperature.  Dilution used for phalloidin 
was 1:200, 0.5 μl in 100 μl assay volume PBS.  The slides were rinsed once with 1XPBS and 
finally treated with 300 μl DAPI (4’, 6-diamidino-2-phenylindole) (0.1 μg/mL), a nuclear staining 
dye.  The slides were rinsed 3 times with 1XPBS for 5 min each,150 µl of DABCO (2% DABCO, 
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80% glycerol in PBS) mounting media was added into each well, covered with the lid and the 
slides were further examined under the confocal microscope Zeiss 510 using filters 420-480, 505-
550, or 560-615. 
2.6. Cell cycle Analysis by Flow Cytometer 
The HDAC inhibitors were also evaluated for their effect on NS-1 cells growth cycle in in vitro 
culture.  For cell cycle studies 1x105 NS-1 cells/mL were seeded into a 25 cm² collagen I coated 
cell culture flask in a total volume of 5 mL.  The cells were allowed to adhere for 24 hours.  The 
NS-1 cell cultures were treated with 1μM vorinostat and/or 2.5ng/mL NGF for 24 and 48 hours. 
The cells were harvested by scrapping in ice cold 1xPBS.  The washed cells from different culture 
flasks were collected in tubes, centrifuged at 200xg for 5 minutes at 40C.  Cells were resuspended 
in 1 mL ice cold 1XPBS.  These cell suspensions were added to 9 mL of cold 70% ethanol with 
constant gentle shaking.  The cell suspensions in 70% ethanol were kept at 40C for 2 hrs.  After 
fixation in ethanol, the cell suspensions were centrifuged at 200g for 10 min at 4°C.  The cell 
pellets were washed with ice cold 1XPBS by centrifuging at 200g for 10 min at 4 °C.  The pellets 
were resuspended in RNase A (3 mL; 100 µg/mL in 1XPBS) and the tubes were incubated at 37°C 
for 30 min.  The RNase solution was removed by centrifugation of the cell suspensions at 200 g 
for 10 min at 4°C.  The supernatants were discarded and the cells were stained by adding 1mL of 
50µg/mL of propidium iodide solution in PBS for 30 min at 4°C.  Further the analysis of cell cycle 
was done using BD Facscalibur through Cell proquest.  Total gated and ungated events recorded 
were 5000. The cell cycle data acquired were analysed with flowJo software.   
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2.7. HDAC Assay: 
HDAC assay was done using Fluoro-de-lys HDAC Fluorometric acivity assay kit (BML-
AK500-0001) (Enzo Life Science, USA). 
Treatment 
The NS-1 (2.5x105 cells per 25cm2 culture flask in total volume of 5mL) were seeded for 
24 hours. The cells were treated with 25 nM trichostatin A for 8, 24, 72 and 96 hours, the cells 
were washed with 1XPBS and harvested. The cell pellets were resuspended in 1X cell lysis buffer 
(Cell Signaling Technology, USA).  Protein contents in cell lysates were determined by Bradford 
assay (Bio-Rad, USA).  The cell lysates were diluted with HDAC assay buffer (50 mM Tris/Cl, 
pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) to get 20 µg protein/25 µL of the lysate.    
Reagent /Dilution preparation 
Fluoro de-lys substrate was diluted 1:200 times in HDAC assay buffer (50 mM Tris/Cl, pH 
8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2). Fluor de LysDeveloper (20x Stock Solution), 
diluted to 1X time in HDAC Assay Buffer before use and Trichostatin A (0.2 mM in DMSO 
(dimethylsulfoxide). e.g. 10μl in 1 mL; final Trichostatin A concentration in the 1x Developer = 
2μM; final concentration on after addition to HDAC/Substrate reaction = 1μM. The cell lysates 
were diluted with HDAC assay buffer -to get 20 µg protein/25 µL of the lysate. The Hela nuclear 
cell extract, supplied with the HDAC assay kit, was used as positive control. 
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Assay protocol 
Assay buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2), or test 
inhibitor/sample was added to appropriate wells of the microtiter plate (Table).  Diluted HeLa 
extract or other TSA treated cell lysate was added to all wells except those that are to be “No 
Enzyme Controls” (Table 2.1).  Diluted Fluor de Lys Substrate and the samples in the microtiter 
plate were allowed to equilibrate to assay temperature (e.g. 25 or 37°C) for 10 minutes.  HDAC 
reactions were initiated by adding diluted substrate (25μl) to each well and mixing thoroughly.  
HDAC reactions were allowed to proceed for 10 minutes and then stopped by adding 50μl Fluor 
de Lys Developer.  Plates were incubated at room temperature (25°C) for 10-15 min.  Signal is 
stable for at least 30 min beyond this time.  Samples were read in a microtiter-plate reading 
fluorimeter capable of excitation at a wavelength in the range 350-380nm and detection of emitted 
light in the range 440-460nm.  
Table 2.1 Assay 
buffer 
 Substrate Mix well by 
pipetting and 
incubate for 10 
min 
Developer Incubation at room 
temperature for 15 min 
Take  reading Blank  
(No enzyme) 
25µl 25µl 50µl 
Sample  25µl 25µl 50µl 
Zero time 25µl 25µl 50µl 
For zero time add substrate just before adding developer  
Table 2.1. Template for HDAC assay 
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2.8. Statistical analysis 
All quantitative data is presented as mean and standard deviations as computed with MS 
Excel and GraphPad Prism 6 software.  The individual data sets were statistically analyzed by 
Students t test and p values were computed to determine statistically significant differences 
between two groups.  One-way analysis of variance (ANOVA) followed by Bonferroni test were 
used to compare multiple groups.  The p values were computed to determine statistically 
significant differences among the groups.     
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CHAPTER 3 
EXPERIMENTAL RESULTS 
3.1. Aim 1: Screen pan and selective HDAC inhibitors for neurotrophic potential and 
induction of neuritogenesis in NS-1 cells 
A large number of natural and synthetic compounds are currently known to inhibit HDACs 
(Dokmanovic et. al., 2007).  The HDACi do not inhibit all HDAC isoforms to the same extent. 
The HDACi have been grouped into pan and selective HDACi based on their isoform selectivity 
and other inhibition characteristics (Balasubramanian et. al., 2009).  Hydroxamic acids (e.g. TSA, 
SAHA, LAQ824, and CBHA) and pyroxamic acids (PXD101 and CRA-026440) are pan-HDAC 
inhibitors, which target class I, II and IV HDACs with variable sensitivities.  Selective HDAC 
inhibitors are relatively specific against individual HDAC isoforms, which may exhibit reduced 
side effects compared to the pan-HDAC inhibitors, while retaining efficacy in specific subsets of 
indications, where each HDAC isoform plays a critical role.  Benzamides (MS275 and CI-994), 
cyclic tetrapeptides (Trapoxin A and depsipeptides) selectively inhibit class I HDACs (Xu et. al., 
2007).  Depsipeptide is currently in a phase II clinical trials for Cutaneous T-cell Lymphoma 
(CTCL) and peripheral T-cell Lymphomas (PTCL) (Rasheed et.al, 2007).  Selective HDACi also 
provide important tools to investigate the role(s) of specific HDAC isoforms in target functions. 
In order to identify the HDACi with potential neurotrophic action, we have evaluated both pan- as 
well as selective HDACi for their neuritogenic action in vitro in NS-1 cells culture. The HDACi 
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were tested alone and also in combination with NGF, the natural neurotrophin. Six HDACi namely, 
SAHA, TSA and Belinostat (as the highly potent pan- HDACi), tubastatin A (a highly selective 
HDAC6 inhibitor), PCI-34051 (a selective HDAC8 Inhibitor) and Tenovin-1 (a selective inhibitor 
of sirtuins SirT1 and SirT2) were selected for initial investigations for neurotrophic action and 
induction of neurite outgrowth in NS-1 cells.  More details about the individual inhibitors are 
summarized as below. 
3.1.1. PCI-34051 
PCI-34051 is a selective HDAC8 inhibitor derived from the low molecular weight 
hydroxamic acid scaffold. PCI-34051 inhibits HDAC8 with a Ki of 10 nM and has greater than 
200 fold selectivity over the HDACs 1, 2, 3, 6 and 10.  PCI-34051 has been shown to induce 
apoptiosis in the T-cell lymphoma cells like Jurkat and HuT78 cells at very low micromolar doses 
(Balasubramanian et. al., 2008).  However, the apoptoic effect of PCI-34051 is seen only in the 
cell lines derived from T-cell lymphoma, but not in solid tumors,  plasma cells, monocytes or the 
cell lines derived from B-cells, even at doses as high as 20 μM.  The cell death induced by PCI-
34051 is caspase dependent and also requires phospholipase C gamma 1 (PLC λ 1) enzymatic 
activity. Induction of PLCλ1 increases calcium mobilization, which in turn results in uptake of 
calcium into mitochondria, release of cytochrome c into the cytosol and activation of caspase 
(Balasubramanian et. al., 2008). 
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Figure 3. 1. Chemical structure of PCI-34051. 
3.1.2. Tubastatin A 
Tubastatin A is a highly potent selective HDAC6 inhibitor with an IC50 of 15 nM. 
Tubastatin A is substantially more selective than the previously known HDAC 6 inhibitor, tubacin.  
Tubastatin A has been known to induce α -tubulin hyperacetylation in primary cortical neurons.  
Tubastatin A has also shown dose-dependent protection of primary cortical neuron cultures against 
glutathione depletion-induced oxidative stress (Butler et. al., 2010).  The α-tubulin is the most 
abundant substrate for tubastatin (Hubbert et. al., 2002). Other HDAC6 substrates include HSP90, 
Cortactin and β-Catenin (Kovacks et. al., 2005; Zhang et. al., 2007; Li et. al., 2008).  The HDAC6 
also binds with ubiquitin and regulates cell protective response to cytotoxic accumulation of mis-
folded and aggregated proteins (Ouyang et. al., 2012).  In several CNS diseases, HDAC6 has 
emerged as a useful target for pharmacological intervention. Selective inhibition of HDAC6 is 
associated with neuronal survival and regrowth after injury, thereby having a huge potential for 
treatment of neurodegenerative disease (Kazantsev and Thompson, 2008; Rivieccio et. al., 2009; 
Butler et. al., 2010). 
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Figure 3. 2. Chemical structure of tubastatin A. 
3.1.3. Tenovin-1 
Tenovin-1 inhibits SIRT1 and SIRT2, the members of the NAD+-dependent class III 
HDACs. Tenovin-1 decreases the protein deacetylase activities of purified human SirT1 and SirT2 
(Lain et. al., 2008).  It has been shown to affect acetylation of SirT1 and SirT2 substrates in cells. 
SirT1 substrate includes histones H1, H3 and H4. SirT1 can induce silencing of chromatin by 
inducing deacetylation of histones H1, H3 and H4 (Vaquero et. al., 2004).  SirT2 is cytoplasmic 
protein and it deacetylases large number of cytoplasmic substrates including α-tubulin (North et. 
al., 2003).  Tenovin-1 is the only sirtuin inhibitor, for which overexpression of SirT1 or SirT2 has 
been shown to impair their effects (Lain et. al., 2008).  Tenovin-1 has been shown to activate and 
elevate acetylated p53 levels, induce apoptosis in vitro, and acetylate histone H4.  Tenovin-1 also 
activates p21 and p53.  Tenovin-1 increases the protein level of p53 within 2 hours of treatment of 
MCF-7 cell lines.  However the mRNA level for p53 was not affected by tenovin-1 (Lain et. al, 
2008)  
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Figure 3. 3. Chemical structure of tenovin-1. 
3.1.4. Belinostat (PXD 101) 
Belinostat is a new hydroxamate derivative and is believed to inhibit class 1 and class 2 
HDACs.  Belinostat is in late stage clinical development for Peripheral T-cell Lymphoma (PTCL).  
Belinostat increases acetylation of both histones and non-histone proteins, resulting in cell cycle 
arrest, apoptosis and a decrease in cell proliferation in tumor cell lines.  In vitro experiments 
showed that belinostat had potent anti-tumor effect at low micromolar potency in several tumor 
cell lines.  Belinostat inhibited tumor growth in animal models at non-toxic concentrations 
(Tumber et. al., 2007; Plumb et.al, 2003; Qian et. al., 2006).  Phase I clinical studies have also 
suggested that belinostat has anti-tumor effect (Hansen et. al., 2005; Marks et. al., 2001). 
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Figure 3. 4. Chemical structure of belinostat. 
3.1.5. Trichostatin A (TSA) 
TSA is an antifungal antibiotic, which inhibits the class I and II HDACs.  TSA is the most 
potent of all the HDAC inhibitors.  It belongs to the group of hydroxamic acid HDACi. TSA 
inhibits the eukaryotic cell cycle during the beginning of the growth stage (Drummond et. al., 
2005), induces cell differentiation, cell cycle arrest, and reversal of transformed cells morphology 
(Yoshida et.al., 1995). 
 
 
Figure 3. 5. Chemical structure of Trichostatin A. 
3.1.6. Suberoylanilide hydroxamic Acid (SAHA)  
SAHA is the first HDACi approved by the U.S. Food and Drug Administration (FDA) for 
the treatment of Cutaneous T Cell Lymphoma (CTCL).  SAHA is a small molecular weight (<300) 
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linear hydroxamic acid compound that inhibits HDACs of Class I & II with IC50 in the range of 
10-100 nM.  SAHA is also referred as vorinostat and marked under the trade name Zolinza. By 
inhibition of HDAC activity, SAHA induces the accumulation of acetylated histones as well as 
non-histone proteins, blocks the proliferation of cultured cells and inhibits tumor growth in a 
variety of animal models (Marks et. al., 2001; Marks and Dokmanovic, 2005).  Administration of 
SAHA orally is able to cross the blood brain barrier, increases histone acetylation and improves 
motor impairment in the R6/2 mouse model of Huntington’s disease (Mitsiades et. al., 2004). 
 
Figure 3. 6. Chemical structure of vorinostat. 
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3.2. Results 
The NS-1 cell cultures were treated with different concentrations of NGF and neurite 
outgrowth was determined as described in experimental section. A dose-dependent effect of NGF 
was confirmed in vitro on NS-1 cells. The NS-1 cells were observed to be significantly more 
responsive than the regular PC12 cells to neurotrophic effects of NGF. Treatment with as low as 
1.25 ng/mL concentration of NGF was able to trigger differentiation and neuritic outgrowth 
measured in terms of mean neurite length in NS- 1 cells as shown in Figure 3.7. At doses 25 and 
50 ng/mL, the saturation of neurite outgrowth was observed.  
The concentrations of 1.25 and 2.5 ng/mL NGF were observed to be significant and sub-
optimal for the neurite growth. These concentrations of NGF were employed in subsequent 
experiments for evaluation of neurotropic potential of HDAC inhibitors and also for interrogation 
of relevant signal transduction pathways. 
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Figure 3.7. Dose response curve of NGF on mean neurite length. NS-1 cells were treated with 
varying concentration of NGF ranging from 0-50 ng/mL. After 72 hours of incubation, cells were 
stained and mean neurite length was calculated by analysis of the digital images of the cells. Dose 
response curve was plotted with concentration of NGF (ng/mL) against mean neurite length. Error 
bars shown here are SD of three independent readings. 
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3.2.1. Evaluation of neurotrophic effects of PCI-34051  
Three concentrations (1, 2.5 and 5 μM) of PCI-34051 were tested on NS-1 cells to evaluate 
the effect of this HDACi on the neuritogenesis. PCI-34051 was tested alone and also in 
combination of NGF (2.5 ng/mL).  The NGF alone (2.5 ng/mL) was tested as a positive control.  
All the doses tested were not cytotoxic to the NS-1cells.  The PCI-34051 mediated neuritogenesis 
was compared with positive control NGF (2.5 ng/mL) and untreated NS-1 cells.  Neurtiogenesis 
was measured in terms of three end points namely, mean neurite length (Figure 3.8.A), numbers 
of neurites/cell (Figure 3.8.B) and neurite length/cells (Figure 3.8.C).  Treatment with PCI at 1 and 
2.5 μM did not produce significant increase in mean neurite length.  However, PCI-34051 at 5μM 
produced significant increase in mean neurite length, neurite length/cell as well as a number of 
neuritis/cells. Thus PCI-34051 at 5 µM produced significant and prominent induction in neurite 
outgrowth, as determined by significant increase in all the three parameters of neurite outgrowth.  
Co-treatment of NS-1 cells with PCI-34051 and NGF produced neuritogenic effect similar to that 
shown by NGF alone. PCI-34051, therefore, did not cause significant effect on the NGF-stimulated 
neurite outgrowth. 
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Figure 3.8.  Effect of PCI-34051 on neurite outgrowth in NS-1 cell. Cells treated with 1, 2.5 
and 5 μM PCI-34051 with and without NGF 2.5 ng/mL for 72 hours. Neurite outgrowth 
significantly increased in PCI-34051 (5 μM) treated cells as indicated by three measured 
parameters in terms of three end points namely, [A] mean neurite length [B] numbers of 
neurites/cell and [C] neurite length/cell. Data represented are mean ± SD of three independent 
experiments. * P< 0.05, ** P< 0.001 compared to control untreated cells.  
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3.2.2. Effect of tubastatin A on neurite outgrowth 
The NS-1 cell cultures were treated with tubastatin A 1, 5 and 10 μM. Cytotoxicity of the 
inhibitor at these doses was also tested.  All the doses of tubastatin A tested for induction of 
neuritogenesis were non-toxic to the NS-1 cells.  Tubastatin A at any dose tested alone did not 
induce significant neurite outgrowth in NS-1 cells measured in terms of three end points i.e. mean 
neurite length (Figure 3.9. A), neurites/cell (Figure 3.9. B) and neurite length/cell (Figure 3.9. C).  
However, only at 5 μM concentration of tubastatin A, there was a significant increase in number 
of neurite/cells as compared to the control untreated cells. NS-1 cells treated with NGF and 
tubastatin A also had significant neurite outgrowth. 
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Figure 3.9. Effect of tubastatin A on neurite outgrowth in NS-1 cells. The NS-1 cell cultures 
were treated with tubastatin A 1, 5 and 10 μM with and without NGF (2.5 ng/mL) for 72 hours. 
Neurite outgrowth was measured in terms of three end points namely, [A] mean neurite length [B] 
numbers of neurites/cell and [C] neurite length/cell. Data represented are mean ± SD of three 
independent experiments.  P value were calculated using student test,* denotes P< 0.05, ** denotes 
P< 0.001 and NS indicates non-significant difference compared to control untreated cells.  
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3.2.3. Effect of tenovin-1 on neurite outgrowth. 
Tenovin-1, an inhibitor SirT1 and SirT2, was evaluated at three concentrations namely, 
2.5, 5.0 and 10 μM for the potential to induce neurite outgrowth in NS-1 cells.  Cytototoxicity of 
tenovin-1 was also monitored.  Tenovin-1 did not show noticeable toxicity on NS-1 cells.  Also, 
tenovin-1 alone at any of concentrations tested did not significantly increase the neurite outgrowth 
in terms of mean neurite length and neurite length/cell.  However, tenovin-1 at 5 and 10 μM 
concentrations led to a significant increase in number of neurite/cell.  Interestingly, tenovin-1 
significantly inhibited the NGF-mediated neuritogenesis in terms of mean neurite length (Figure 
3.10.A), neurites/cell (Figure 3.10.B) and neurite length/cell (Figure 3.10.C). 
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Figure 3.10. Effect of tenovin-1 on neurite outgrowth in NS-1 cell. Cells were untreated and 
treated with tenovin-1 2.5μM, 5 μM and 10 μM with and without NGF 2.5 ng/mL for 72 hours. 
Tenovin-1 alone at any concentration tested did not significantly increased the neurite outgrowth 
in terms of mean neurite length and neurite length/cell. However, tenovin-1 at 5 μM and 10 μM 
concentration lead to a significant increase in neurite/cell., tenovin-1 significantly inhibited the 
neurite outgrowth induced by NGF as indicated by three measured parameters in terms of three 
end points namely, [A] mean neurite length [B] numbers of neurites/cell and [C] neurite 
length/cell. Data represented are mean ± SD of three independent experiments.  P value were 
calculated using student t test, * denotes P< 0.05, ** denotes P< 0.001 and NS indicates non 
significance compared to control untreated cells. 
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3.2.4. Effect of belinostat on neurite outgrowth 
Belinostat, a pan HDACi also referred as PDX 101, has been clinically approved by the 
US-FDA for the treatment of peripheral T-cell lymphoma.  Belinostat was tested for neurotrophic 
action at 0.25 and 0.5 μM concentrations.  Both the concentrations of belinostat tested did not 
affect the viability and growth of the NS-1 cells.  Also, belinostat alone did not induce neurite 
outgrowth in NS-1 cells.  However, belinostat significantly inhibited the neurite outgrowth in NGF 
treated cells.  The neurite outgrowth was measured in terms of mean neurite length, (Figure 3.11.A) 
neurites per cell (Figure 3.11.B) and neurite length/cell (Figure 3.11.C.  The NS-1 cells treated 
with belinostat and NGF showed significantly lower neurite length compared to those treated with 
NGF alone.     
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Figure 3.11.  Effect of belinostat on neurite outgrowth in NS-1 cells. Cells were treated with 
belinostat (0.25, and 0.5 μM) with and without NGF (2.5 ng/mL) for 72 hours. Neurite outgrowth 
was measured in terms of three end points namely, [A] mean neurite length [B] numbers of 
neurites/cell and [C] neurite length/cell. Data represented are mean ± SD of three independent 
experiments.  P value were calculated using student test,* denotes P< 0.05, ** denotes P< 0.001 
and NS indicates non-significant difference compared to control untreated cells. 
  
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
Control Belinostat 0.25µMBelinostat 0.5µM
M
e
a
n
 
n
e
u
r
it
e
 l
e
n
g
th
( 
μ
m
)
0 ng/ml NGF
1.25 ng/ml NGF
0.00
5.00
10.00
15.00
20.00
25.00
Control Belinostat 0.25µM Belinostat 0.5µM
N
e
u
r
it
e
 l
e
n
g
th
 /
c
e
ll
 (
μ
m
)
0 ng/ml NGF
1.25 ng/ml NGF
0.00
0.50
1.00
1.50
2.00
2.50
Control Belinostat 0.25µM Belinostat 0.5µM
N
u
m
b
e
r
 
o
f 
n
e
u
r
it
e
s
/c
e
ll
0 ng/ml NGF
1.25 ng/ml NGF
**
**
*
NS
NS
NS
**
**
A
C
B
60 
 
3.2.5. Effect of Trichostatin A on NS-1 cells differentiation 
TSA at the concentrations higher than 25 nM resulted in >30% decrease in viability of NS-
1 cells.  However, TSA caused significant lower cytotoxicity in NS-1 cell cultures co-treated with 
NGF. Co-treatment with TSA (50 nM) and NGF (1.25 ng/mL) was found to be non-toxic.  TSA 
however did not show noticeable neurotropic action as evaluated by overall neurite outgrowth in 
NS-1 cell cultures treated with TSA alone and co-treated with TSA and NGF.  In order to check 
whether TSA is bringing about any change in HDAC activity, the NS-1 cell cultures were treated 
with TSA 50 nM and NGF 1.25 ng/mL for 8, 24, 72 and 96 hours.  HDAC activity in the cell lysate 
was determined using fluor-de-lysHDAC fluorometric activity assay kit from ENZO life sciences. 
The results showed that HDAC activity was lowest at 8 hours in TSA treated cells as 
compared to the untreated and NGF treated cells.  However, at 24 and 72 hours in TSA treated 
samples, the HDAC activity was recovered and followed the trend similar to untreated and NGF 
treated cells figure 3.12. 
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Figure 3.12. Effect of Trichostatin A on HDAC activity in NS-1 cells. The NS-1 cell cultures 
were treated with TSA (25 nM) and NGF (2.5 ng/mL) for 8, 24, 72 and 96 hours. The HDAC 
activity (AFU) was measured in the lysates of treated and control NS-1 cell cultures following the 
instructions in the protocol.  
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3.2.6. Effect of vorinostat (suberoylanilide hydroxamic scid- SAHA) on neurite outgrowth 
Vorinostat was evaluated for cytotoxicity against the NS-1 cells. The vorinostat 
concentrations at 2.5 µM and 5μM were toxic (Figure 3.13) and the 1µM vorinostat was 
completely safe for the NS-1 cells.  
 
Figure 3.13. Effect of vorinostat on growth and viability of NS-1 cells. Neuroscreen-1 cells 
were treated with vorinostat for 72 hrs.  At 48 hours, alamarBlue was added, viability was 
measured at 72 hours using alamarBlue assay. Error bars shown are S.D. (Standard deviation) of 
triplicate observations. . 
In subsequent studies, NS-1 cells were treated with vorinostat (1 µM) and NGF (2.5 ng 
mL-1) for 72 hours to investigate their neurotrophic actions Vorinostat (SAHA) at 1 µM 
concentration, independent of NGF, stimulated significant neurite formation in NS-1 cells (Figure 
3.14 A) compared to control cell culture.  The neuritic outgrowth induced by vorinostat was 
comparable to the effect of NGF.  The induction of neuritic out growth in NS-1 cells by 
combination of vorinostat and NGF was similar to that produced by the NGF alone.  Further, the 
neurite outgrowth in NS-1 cells was quantitatively measured and presented as three end points 
namely, mean neurite length (Figure 3.14 B), numbers of neurites/cell (Figure 3.14 C) and neurite 
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length/cell (Figure 3.14 D).  The independent and significant neurotrophic action of vorinostat was 
confirmed based on significant increase in all three parameters, namely, mean neurite length, 
numbers neurites/cell and neurite length/cell.  Neuritogenesis induced by vorinostat was 
marginally less prominent as compared to NGF induced neuritogenesis.  Vorinostat in combination 
with NGF had a similar effect on neurite outgrowth as NGF treatment alone. 
 
Figure 3.14. Induction of neurite outgrowth in NS-1 cells by vorinostat treatment.  [A] 
Microscopic digital images of NS-1 cells (i) Control NS-1 cells (ii) NS-1 cells treated with 1 µM 
vorinostat for 72 hrs. (iii) NS-1 cells treated with NGF (2.5 ng/ml) for 72 hrs (positive control). 
(iv) NS-1 cells treated with vorinostat (1µM) + NGF (2.5 ng/mL). neurite outgrowth 
/neuritogenesis significantly increased in  vorinostat treated cells as indicated by three measured 
parameters in terms of three end points namely, [B] mean neurite length [C] numbers of 
neurites/cell and [D] neurite length/cell. Data represented are mean ± SD of three independent 
experiments. * P< 0.05, compared to control.  
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3.3. Aim 2: Interrogate cellular and molecular mechanisms of neurotrophic actions of 
neurotrophic HDAC inhibitors 
Neuritogenesis, the formation of neurites from a cell, is the initial step in the development 
of a mature neuronal morphology (Craig and Banker, 1994).  The key morphological features of 
neuritogenesis include initial branching of neurites followed by elongation of axons and branching 
of dendrites (Kiryushko et. al., 2004).  Neuritogenesis is a key cellular process necessary for proper 
development of the adult nervous and neuronal regeneration.  Neurite extension from the soma 
depends on precise cytoskeletal and adhesion dynamics induced by sensing of extracellular signals.  
This process is similar to the directional pseudopodia formation involving regulated actin-
mediated membrane protrusion and signal transduction processes.  Neurite outgrowth is a vital 
event in neuronal development, formation and remodeling of synapses, response to injury, repair 
and regeneration of damaged neurons.  Understanding the mechanism of neurotrophic processes 
like neurite outgrowth and neuronal survival is crucial for brain development studies and treatment 
of various neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease (Jones 
et. al., 2001). 
Neurotrophic factors have been extensively studied with regard to their role in neuronal 
development and synaptic plasticity.  In in vitro and in vivo studies, neurotrophic factors have been 
shown to promote neurite outgrowth, neuronal differentiation, proliferation, survival, and 
regeneration.  Neurotrophic factors are reported to increase the number and length of neurites 
formed from the parent cell body of cultured neurons (Takano et. al., 2002).  They also play an 
important role in synapse formation during neurite outgrowth (Munno et. al., 2000) as well as for 
synaptic plasticity (Schinder and Poo, 2000).  Neurotrophic factors such as nerve growth factor 
(NGF), brain derived nerve factors (BDNF), neurotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5) 
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are known to promote differentiation and survival of neurons via activation of tropomyosin-
receptor-kinase (Trk) receptors namely, TrkA, TrkB and TrkC respectively.  These receptors are 
present on the cell membrane of neurons (Kaplan and Miller, 1997).  Trk receptors are a family of 
tyrosine kinases that regulate synaptic strength and plasticity in the mammalian nervous system.  
Trk receptors affect neuronal survival and differentiation through several signal transduction 
cascades.  However, the activation of these receptors also has significant effects on functional 
properties of neurons (Huang & Reichardt, 2003). 
Signaling pathways linked to the process of neurite extension and survival are intricate, 
involving complex signaling events.  These signaling pathways mainly function through protein 
phosphorylation cascades.  Three of the pathways studied downstream of the Trk receptors are (I) 
Ras/mitogen-activated protein kinase (MAPK) pathway, (II) Phosphatidylinositol-3 kinase 
pathway (PI3-K) /AKT pathway, and (III) Phospholipase C-gamma 1 (PLCG1) pathway (Shimoke 
et. al., 2009).  The MAPK cascade is the most extensively characterized signaling pathway 
controlling the neuritogenesis (Vaudry et.al, 2002).  NGF-stimulated pathway has been the most 
extensively investigated signaling mechanism for neuritic outgrowth (Figure 3.15).  In initial 
screening of several HDACi, vorinostat exhibited the most promising neurotrophic action. 
Vorinostat independently induced significant neurite outgrowth in NS-1 cells, similar to that of 
NGF.  We further investigated the mechanism of vorinostat mediated neurite outgrowth by 
interrogating the signaling pathways linked earlier to NGF-mediated neuritogenesis.  It was 
hypothesized that vorinostat stimulated neuritogenesis follows the mechanism similar to the NGF-
mediate signaling for neurite outgrowth.  This hypothesis was verified by employing selective 
inhibitors of the MAPK pathway (U0126 and PD98059), PI3K mediated signaling (Ly294002) 
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and TrkA (GW441756).  The predicted role of cAMP-linked pathway was also investigated with 
the SQ22536, a selective inhibitor of adenylate cyclase. 
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Adopted from http://www.cellsignal.com/pathways 
Figure 3.15- The NGF-linked TrkA mediated neurotrophin signaling pathway. Upon binding 
of NGF to TrKA, Ras is activated which in turn activates c-Raf.  Activation of MEK1 and MEK2 
occurs through phosphorylation of two serine residues by Raf-like molecules. MEK1 and MEK2 
are dual-specificity protein kinases that function in a mitogen activated protein kinase (MAPK) 
cascade controlling cell growth and differentiation. Phosphoinositide 3-kinase and its downstream 
effector kinase PKB/Akt are also activated by NGF playing role in neuronal survival. 
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3.3.1. The vorinostat induced neuritogenesis in NS-1 cells may occur through activation of 
ERK/MAPK pathway 
For cytotoxicity & neuritogenesis assays 1000 cells/well were seeded onto collagen IV 
coated 96 well plates in RPMI 1640 medium and incubated for 24 hrs at 37°C with 5% CO2.  The 
cell cultures were pretreated with the inhibitors of MEK1/2 (PD98059 or U0126) or PI3K 
(LY294002) (10 µM) for 1 hour followed by treatment with vorinostat (1 µM) and/or NGF (2.5 
ng/ml) (positive control).  0.025% of DMSO was used as a negative control.  Cytotoxicity of these 
inhibitors was measured at 72 hrs post-treatment and cells were further analyzed for neuritic 
outgrowth by neuritogenesis assay as described in experimental section.  Both the NGF- and 
vorinostat-induced differentiation/neuritogenesis were significantly attenuated in the presence of 
MEK inhibitors (PD98059 & U0126) as well as PI3K inhibitors (LY294002) (Figure 3.16 and 
3.17).  Neuritogenesis was measured in terms of mean neurite length (Figure 3.17.A), neurite 
length/cell (Figure 3.17.B) and neurites/cell (Figure 3.17.C).  However, the effect of LY294002 
(PI3K inhibitor) was less prominent as compared to the MEK inhibitors on neurite outgrowth.  
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Figure 3.16 The NS-1 cells treated with vorinostat (1µM), NGF (2.5ng/mL), PD98059, U0126 
and LY294002 alone and combinations as indicated. Neurite outgrowth and cytoxicity were 
measures as described in the experimental section and quantitative results are shown in Figure 
3.17.  
NGF
NGF + PD98059 NGF + U0126 NGF + LY294002
Control
PD98059 U0126 LY294002
Vorinostat
Vorinostat + PD98059 Vorinostat + U0126 Vorinostat + LY294002
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Figure 3.17. Vorinostat induced neuritogenesis in NS-1 cells is dependent on activation of 
MEK. NS-1 cells were treated with vorinostat (1µM), NGF (2.5 ng/mL), and/or inhibitors (10 
µM) of MEK1/2 (PD98059 and U0126) and PI3K (LY294002) pathways for 72 hrs and assayed 
for neurite outgrowth. The neurite outgrowth was measured as [A] Mean neurite length: ratio 
between total neurites length and number of cells counted. [B] Neurites/cell: ratio between number 
of neurites and number of cells counted and [C] neurite length/cell: ratio between total neurites 
length and number of cells counted.  The data sets are the mean ± SD of three independent 
experiments. * P< 0.05, ** P< 0.001 and ns indicates non-significant difference compared to 
control cells vs NGF and vorinostat and NGF and vorinostat treated cells vs inhibitor in 
combination with vorinostat and NGF. 
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3.3. 2. Vorinostat mediated phosphorylation of ERK is abolished in the presence of U0126, 
an inhibitor of MAPK   
Both vorinostat and NGF treatment produced a time-dependent activation of ERK (Figure 
3.18.).  NS-1 cells were treated with 1 µM vorinostat and 2.5 ng/mL NGF with and without U0126 
for 5, 15, 30, 60 and 120 minutes.  The cell lysates were subjected with SDS-PAGE and western 
blot analysis and probed with anti-pERK antibodies.  Vorinostat treatment produced prominent 
activation of phosphorylation of ERK at 30 minutes, which increased further up to 2 hours post-
treatment.  The vorinostat mediated activiation of ERK was completely abolished in the presence 
of U0126. NGF-mediated phosphorylation of ERK was rapid as early as 5 minutes and was also 
attenuated in the presence of UO126 at all the time point tested.  The results further confirm 
neurotrophic actions of vorinostat through activation of the ERK signaling pathway.  
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Figure 3.18. Effect of U0126 on vorinostat and NGF mediated ERK phosphorylation. NS-1 cells 
were treated with vorinostat (1 μM) and NGF (2.5 ng/mL) with and without U0126 for 5, 15, 30, 
60 and 120 minutes. The blots were probed with anti-pERK1/2 antibody.  Vorinostat mediated 
activation of ERK1/2 phosphorylation (pERK) was detected within 30 min after the treatment and 
increased at 2 hrs. The vorinostat mediated ERK phosphorylation was completely abolished in the 
presence of U0126.  Similarly NGF mediated ERK phosphorylation was also reduced in the 
presence of U0126 at all the time points. Total ERK levels were also checked. β-Actin was used 
as loading control.   
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3.3. 3. Vorinostat mediated activation of MEK-ERK1/2 signaling is dependent on TrKA-
mediated signaling 
As vorinostat induced neurite outgrowth required activation of ERK, it was hypothesized 
that it may involve activation of the upstream kinase (TrkA), like NGF-mediated neurite 
outgrowth.  To verify this hypothesis, vorinostat mediated neuritogenesis was investigated in the 
presence or absence of GW441756 (1 µM), the inhibitor of TrkA.  The NS-1 cell cultures were 
pre-treated with GW441756 for 1 hour.  Then vorinostat and NGF were added to the pretreated 
cultures. (Figure 3. 19.)  After 72 hrs treatment, cells were stained with Giemsa and neurite 
outgrowth was measured with NIS element software.  Endpoints measured were mean neurite 
length (Figure 3. 19. A) and neurite length/cell (Figure 3. 19. B).  There was a significant reduction 
in neurite outgrowth measured in terms of mean neurite length and neurite length/cell in vorinostat 
treated cells in presence of the TrkA inhibitor GW441756.  In NS-1 cell cultures treated with 
GW441756 and NGF a significant reduction in the neurite outgrowth was observed.  These results 
suggest that vorinostat mediated neuritogenesis involves activation of TrkA receptor similar to that 
in case of NGF-mediated neurotrophic pathway. 
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Figure 3.19.  Vorinostat mediated neurite outgrowth in NS-1 cells was attenuated in presence 
of TrkA inhibitor, GW441756. The vorinostat induced neuritogenesis in NS-1 cells was 
dependent on activation of upstream kinase TrkA. NS-1 cells were pre-treated with GW441756 
(Trki) (1µM) for 1 hour, followed by treatment with vorinostat (1 µM) or NGF (2.5 ng/mL), for 
72 hrs and assayed for neurite outgrowth. The neurite outgrowth was measured as [A] Mean neurite 
length: ratio between total neurites length and number of cells counted. [B] neurite length/cell: 
ratio between total neurites length and number of cells counted.  The data sets are the mean ± SD 
of three independent experiments. * P< 0.05, ** P< 0.001 compared to control cells vs NGF and 
vorinostat and NGF and vorinostat treated cells vs inhibitor in combination with vorinostat and 
NGF. 
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3.3. 4. Vorinostat mediated phosphorylation of ERK was attenuated in the presence of TrkA 
inhibitor GW441756 
As vorinostat mediated neurite outgrowth was attenuated in presence of TrkA inhibitor, we 
further checked, whether activation of ERK phosphorylation induced by vorinostat was also 
reduced in the presence of TrkA inhibitor. NS-1 cells (2.5x 105) were seeded onto collagen I coated 
culture flasks and allowed to adhere for 24 hours.  The cells were treated with vorinostat (1 µM 
and 2.5 µM) with and without GW441756 for 3 hours.  Cells were harvested, lysates ware prepared 
and analyzed by SDS-PAGE Western blotting using antibody against anti-pERK.  There was 
significant activation of ERK at both the doses of vorinostat tested and this activation of ERK in 
terms of ERK phosphorylation was completely abolished in the presence of GW44756 (Figure 
3.20).  The results clearly demonstrate the involvement of upstream kinase TrkA in vorinostat 
mediated ERK phosphorylation and activation of neuritic outgrowth. 
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Figure 3. 20.  Effect of TrkA inhibitor on vorinostat mediated ERK phosphorylation.  NS-1 
cells were treated vorinostat (1 and 2.5 μM) with and without 1 μM GW441756 for 3 hours. The 
lysates were analyzed by SDS-PAGE and blots were probed with anti pERK1/2 antibody. 
Vorinostat mediated activation of ERK1/2 phosphorylation (pErk) was abolished in presence of 
GW441756 (TrkA).  
 
3.3. 5. Vorinostat induces hyperacetylation of histones H3 and H4 
To determine whether changes in histone acetylation profile also occur during 
differentiation of NS-1 cells and to verify that vorinostat was acting as an HDAC inhibitor in the 
cells, we compared changes in acetylation of Histone H3 and H4 in untreated and vorinostat treated 
cells (Figure 3.21.).  To detect acetylation of histone H3 and H4, NS-1 cells were treated with 
vorinostat (1 and 2.5 μM) for 24 hrs. Protein extracts were prepared  from treated and untreated 
cells and analysed by Western blot with antibodies specific for acetyl-histone H3 (Lys 9) and 
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acetyl-Histone H4 (Lys 8).  We observed hyperacetylation of histones H3 and H4 in vorinostat 
treated NS-1 cells, while in untreated cells we did not detect any level of acetylation of histones 
H3 and H4.  The result suggests that there was significant hyperacetylation of H3 and H4 in 
vorinostat treated cells.  Increased in neuronal differentiation by vorinostat may be related to the 
decrease in HDAC activity.  To further confirm the effect of vorinostat treatment on histone 
acetylation and deacetylation functions in NS-1 cells, the changes in acetylation of histones H3 
and H4 were investigated.  The steady state levels of histones were same in all samples. 
 
Figure 3.21. Effect of vorinostat on acetylation of histones H3 and H4. NS-1 cells treated with 
vorinostat (1 and 2.5 μM) for 24 hrs. Western blotting was done and samples were probed with 
acetyl H3 and H4 antibodies.  Vorinostat (1 and 2.5 μM) doses induces hyperacetylation of 
histones H3 and H4 at 24 hours Total histone H3 and H4 were also checked, which were unaltered. 
3.3. 6. Vorinostat induces hyperacetylation of α-tubulin 
To determine whether changes in acetylation of α-tubulin occur in vorinostat treated NS-1 
cells during differentiation, we checked the acetylation of α-tubulin in the cells treated with 
vorinostat for 8 hrs and 24 hrs.  The cell extracts were subjected to SDS-PAGE and Western blot 
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analysis and probed with antibodies against acetylated-α-tubulin (lys 40).  Vorinostat, dose-
dependently produced hyperacetylation of α-tubulin at 8 hours as compared to untreated cells 
(Figure 3.22.).  However at 24 hour, hyperacetylation of α-tubulin was observed with 2.5 μM 
vorinostat treatment, while at 1 μM no significant hyperacetylation of α-tubulin was observed.  
Total tubulin levels were also checked.  The level of total tubulin was unchanged in both treated 
as well as untreated cells. 
 
Figure 3. 22.  Effect of vorinostat on acetylation of α–tubulin.  NS-1 cells treated with vorinostat 
(1 and 2.5 μM) for 8 hrs and 24 hrs.  Western blotting was done and samples were probed with 
anti acetylated-α-Tubulin antibody.  Vorinostat induced hyperacetylation of α-tubulin at 8 hrs and 
24 hrs as compared to control. Total tubulin levels were also checked.  
Further the effect of vorinostat on acetylation of tubulin was also evaluated in situ in NS-
1 cells.  The NS-1 cells (1X105) were seeded onto an ibidi microchamber collagen IV coated 4 
well plastic slide. The cells were allowed to adhere for 24 hrs and then treated with vorinostat (1 
µM) or NGF (2.5 ng/mL) for 6 hours, and immunostained with a rabbit monoclonal antibody 
against acetylated α-Tubulin (Lys40) (D20G3) XP®. NS-1 cells treated with vorinostat showed 
increased levels of acetylated tubulin in the cytoplasm as compared to the untreated and NGF 
treated cells (Figure 3.23).  Results suggest that treatment with vorinostat leads to increase in 
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acetylation of α-tubulin in NS-1 cells.
 
Figure 3. 23.   Immuno-localization of acetylated a-tubulin in NS-1 cells treated with 
vorinostat and NGF.  Treatment of NS-1 cells with vorinostat (1µM) for 6 hours resulted in 
hyperacetylation of α-tubulin. A) Control cells with less staining for acetylalted α-tubulin (green) 
B) Vorinostat treated cells with higher staining for acetyl α-tubulin (green) C) NGF treated cells 
with less staining for acetyl α-tubulin.  The cells were also stained with DAPI (blue color) for 
localization of cell nucleus. 
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3.3. 7. Vorinostat treatment induces growth arrest in NS-1 cells: The cell cycle analysis. 
For cell cycle analysis, the NS-1 cells (1×106) were serum starved for 18 hours before 
treatment with vorinostat and NGF for 24 and 48 hours.  The NS-1 cells were treated with 
propidium iodide and analyzed by flow cytometry for cell cycle analysis.  Treatment of NS-1 cells 
with vorinostat resulted in significant decline in the percentages of cells in the S phase compared 
with control cells, indicating the cell-cycle arrest by the vorinostat.  While treatment of NS-1 cells 
with  vorinostat and NGF resulted in  50% decline in  percentage of cell population at S phase as 
compared to control cell at 24 hrs and 48 hours( Figure 3.24 A and B) and Figure (3.24 C and D). 
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Figure 3. 24- Effect of vorinostat and NGF treatment after 24h on cell cycle of NS-1 cells as 
analyzed by flowcytometry.  Fig A shows a bar diagram for average % of NS-1 cells population 
in each phase of the cell cycle at 24 hour.  Figure B shows histograms of NS-1 cells population in 
each phase of the cell cycle at 24 hour. The data sets are the mean ± SD of three independent 
experiments. * P< 0.05 compared to control cells vs NGF and vorinostat. 
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Figure 3. 24- Effect of vorinostat and NGF treatment after 48h on cell cycle of NS-1 cells as 
analyzed by flowcytometry.  Fig C shows a bar diagram for average % of NS-1 cells population 
in each phase of the cell cycle at 48 hour.  Figure D shows histograms of NS-1 cells population in 
each phase of the cell cycle at 48 hour. The data sets are the mean ± SD of three independent 
experiments. * P< 0.05 compared to control cells vs NGF and vorinostat. 
 
3.3. 8. Effect of adenylate cyclase Inhibitor on vorinostat mediated neuritogenesis in NS-1 
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In order to determine the role of cAMP pathway in vorinostat mediated neuritogenesis, 
SQ22536, a selective inhibitor of adenylate cyclase was used.  NS-1 cells were pretreated with 
SQ22536 for 1 hour, followed by treatment with NGF (2.5 ng/mL) and vorinostat (1μM).  DMSO 
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neuritogenesis measured in terms of three parameters namely, (A) Mean neurite length, (B) 
Number of neurites/cell and (C) Neurite length/cell was significantly potentiated in the presence 
of the adenylate cyclase inhibitor(Figure 3. 25).  However, NGF mediated neuritogenesis was not 
significantly affected by the treatment with SQ22536.  
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Figure 3. 25. Analysis of vorinostat mediated neurite outgrowth in the presence of adenylate 
cyclase inhibitor (SQ22536).  NS-1 cells were pre-treated with SQ22536 (200 µM) for 1 hour, 
followed by treatment with vorinostat (1 µM) and NGF (2.5 ng/mL).  The neurite outgrowth was 
measured as. [A] Mean neurite length: ratio between total neurites length and number of cells 
counted, [B] Number of neurites/cell and [C] Neurite length/cell: ratio between total neurites 
length and number of cells counted.  The data sets are mean±SD of three independent experiments. 
* P< 0.05, ** P< 0.001 compared to control cells vs NGF and vorinostat and NGF and vorinostat 
treated cells vs inhibitor in combination with vorinostat and NGF respectively. P values comparing 
control vs SQ22536 and NGF vs NGF+SQ22536 were non-significant (ns). 
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3.3. 9. Effect of belinostat and tenovin-1 on ERK phosphorylation 
Vorinostat mediated neurite outgrowth involves activation of ERK.  Belinostat and 
tenovin-1 did not induce neurite outgrowth; we hypothesized that belinostat and tenovin-1 would 
not induce activation of ERK phosphorylation.  The results presented in Figure 3.26 show that 
belinostat (Figure 3.26A) and Tenovin-1 (Figure 3.26B) alone did not induce ERK 
phosphorylation.  However, there was significant increase in the level of phosphorylation in 
belinostat and tenovin-1 treated cells in combination with NGF.  
 
Figure 3.26. Effect of [A] belinostat and [B] tenovin-1 treatment on ERK phosphorylation.  
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3.3. 10. Effect of HDAC inhibitors on acetylation of H3 and H4 
The effect of other HDAC inhibitors screened for neurite outgrowth on acetylation of 
histones H3 and H4 was also checked. NS-1 cells were treated with vorinostat (1 and 2.5 μM), 
belinostat (0.25 and 0.5 μM), tubastatin-A (5 and 10 μM), PCI-34051 (5 μM) and tenovin-1 (10 
μM) for 24 hours.  Vorinostat, belinostat, and tubastatin-A induced hyperacetylation of histones 
H3 and H4. However, PCI-34051 and tenovin-1 did not induce hyperacetylation of H3 and H4. 
(Figure 3.27.).  The steady state level of histones H3 and H4 remained unchanged.  
 
Figure 3.27. Effect of treatment with HDAC inhibitors on acetylation Histone H3 and H4 in NS-
1 cells.  
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3.3. 11. Effect of HDAC inhibitors on acetylation of α-tubulin 
The HDAC inhibitors screened for neurite outgrowth were also evaluated for the effect on 
acetylation of α-tubulin in NS-1 cells.  The NS-1 cells were treated with vorinostat (1 and 2.5 μM), 
belinostat (0.25 and 0.5 μM), tubastatin-A (5 and 10 μM), PCI-34051 (5 μM) and tenovin-1 (10 
μM) for 24 hours.  Tubastatin-A induced hyperacetylation of α-tubulin in NS-1 cells.  However, 
belinostat, PCI-34051 and tenovin-1 did not induce hyperacetylation of α-tubulin in NS-1 cells.  
Vorinostat treatment produced significant hyperacetylation of α-tubulin at 8 hours as reported in 
previous experiments (Figure 3.22); however, longer 24 hours treatment did not produce much 
hyperacetylation of -tubulin.  Further, none of these treatments produced significant change in 
steady state levels of -tubulin (Figure 3.28.).  
 
Figure 3. 28. Effect of HDAC inhibitors on acetylation of α-tubulin in NS-1 cells. 
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CHAPTER 4  
DISCUSSION 
Neuritogenesis, formation of neurites by neuronal cells, is the initial step in the 
development of a mature neuronal morphology (Dotti et. al., 1988; Craig and Banker, 1994).  The 
key morphological features of neuritogenesis include branching of neurites followed by elongation 
of axons and branching of dendrites (Kiryushko et. al., 2004).  Neurite outgrowth is a vital event 
in neuronal development. It also plays an important role in formation, and remodeling of synapses, 
response to injury, and regeneration.  Thus, understanding the mechanism of neurotrophic 
processes like neurite outgrowth and neuronal survival is crucial for studies related to brain 
development, pathophysiology and treatment of various neurodegenerative disorders like 
Alzheimer’s and Parkinson’s diseases (Kaplan and Miller, 1997). 
Neurotrophic factors have been extensively studied with regard to their role in neuronal 
development and synaptic plasticity.  In in vivo and in vitro studies, neurotrophic factors have been 
shown to promote neurite outgrowth, neuronal differentiation, proliferation, survival, and 
regeneration (Takano et.al, 2002; Munno et.al, 2000; Schinder et.al, 2000).  However, as treatment 
modalities, neurotrophic factors are large polypeptide molecules and have limited permeability 
across the blood brain barrier.  Also, they are easily metabolized by peptidases, which pose the 
greatest barrier for their therapeutic application (Maruoka et.al, 2011).  Therefore, the small 
molecule neurotrophic compounds that can mimic the functions of intrinsic neurotrophic factors 
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could serve as good alternates for therapeutic use in treatment of neurodegenerative diseases and 
neuronal injuries (More et. al., 2012; Longo and Massa, 2013).  
Recent reports have demonstrated neuroprotective and neuroactive properties of small 
molecular weight inhibitors of histone deacetylases (HDACs) and their potential use in treatment 
of neurological disorders (Camelo et. al, 2005; Wiech et. al, 2009; Xu et. al, 2011).  HDACs 
catalyze the removal of acetyl groups from histones and non-histone proteins and are major 
epigenetic regulators (Hildmann et. al, 2007).  Within the last decade, many studies have 
demonstrated neuroprotective effects of HDAC inhibitors (HDACi) (Chuang et. al, 2009).  HDACi 
are recognized as potential anticancer agents (Slingerland et. al, 2014; Bose et. al, 2014) and also 
play important role in inducing neurite outgrowth and neuroprotection (Xu et. al, 2011).  In 
diseased neurons, HDACi, by reducing histone deacetylation, can restore transcriptional balance 
and thereby delay or stop cellular degeneration.  It is considered that neurotrophic activities of 
HDACi may be epigenetically controlled by acetylation of histones as well as non-histone proteins 
such as transcription factors (Sterner and Berger, 2000).  During neuronal development in the 
peripheral nervous system, regulation of transcription by epigenetic modifications has been 
reported to play an important role in neurite outgrowth and neuroprotection (Guab et. al, 2010).  
Evidence for a neuroprotective role of HDACi has been developed in experimental models of 
various neurodegenerative diseases such as Huntington Disease (Gardian et. al, 2005), 
amyotrophic lateral sclerosis (Petri et. al, 2006), and multiple sclerosis (Camelo et. al, 2005). 
However, the precise mechanisms of the neuroprotection are not clearly understood. 
In a recent comprehensive study with monoaminergic and neuropeptidergic neurons the 
global expression and localization of the HDAC protein family from HDAC1 to HDAC11 was 
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studied in corticotropin-releasing hormone, oxytocin, vasopressin, agouti-related peptide (AgRP), 
pro-opiomelanocortin (POMC), orexin, histamine, dopamine, serotonin, and noradrenaline 
neurons (Takase et. al., 2013).  The study indicated the differential expression of HDACs in 
monoaminergic and neuropeptidergic neurons, which may be crucial for the maintenance of 
biological characteristics of the specific neurons and their differential response to physiological 
and environmental factors (Takase et. al., 2013).  Considering the possible neuroprotective and 
neurotrophic role of the HDACi, the primary aim of this study was to examine the potential of 
HDACi in modulating neuritogenesis in NS-1 cells, and to interrogate the underlying cellular and 
molecular mechanisms involved. 
4.1 Differential neurotrophic responses of pan and isoform selective HDACi  
The pan HDACi namely, vorinostat, TSA and belinostat as well as isoform specific 
inhibitors namely, PCI-34051 (HDAC8) and tubastatin A (HDAC6), tenovin-1 (SirT1&2) were 
tested for their effects in vitro on the neurite outgrowth in NS-1 cells to ascertain the roles of 
HDACs in the process of neurite outgrowth.  Evaluation of as isoform specific inhibitor would 
lead to the determination of target-specific functions of HDAC isoforms in the neuritogenesis 
process.  Differential responses of individual HDACi on direct and NGF-stimulated neurite 
outgrowth indicate variable functions of different HDAC isoforms in this process.  Among the 
battery of HDACi tested alone and in combination with NGF, vorinostat exhibited the most 
prominent independent neurotrophic action on NS-1 cells. Qualitatively and quantitatively the 
neurotrophic action of vorinostat was similar to the NGF.  The NGF is neurotrophin and a cytokine, 
which is mainly produced and secreted by hypothalamus, pituitary glands and also several other 
tissues as well as cell types (McAllister, 2001).  Impairments of NGF production and functions 
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have been implicated in several neuronal and non-neuronal disorders.  The most prominent clinical 
significance of NGF has been in the prevention of neurodegeneration and also in neuroregeneration 
(Allen and Dawbarn, 2006).  Other hydroxamic acid HDACi tested in our study namely, TSA and 
belinostat exhibited different responses compared to vorinostat regarding the effect on the neurite 
outgrowth in NS-1 cells.  TSA at all doses did not induce noticeable neurite outgrowth in NS-1 
cells.  However, previous studies have reported contrasting results regarding neurotropic potential 
of TSA.  TSA promoted neurogenesis, neurite outgrowth, synaptic plasticity and neuroprotection 
in primary rat cortical neurons following ischemic insult (Hasan et. al., 2013).  Treatment with 
TSA increased neurite length in rat cultured cerebellar granule neurons and in cerebral cortical 
neurons presumably through acetylation of p53 (Maruoka et. al., 2011).  TSA was also found to 
induce neurite outgrowth in PC12 cells by expression of early gene IEG nur77.  The induction of 
neurite outgrowth in PC12 cells was prevented with C646, an inhibitor of HAT (histone acetyl 
transferase) (Tomioka et. al, 2014).  However, a study by Futamura et. al., (1995) has shown that, 
TSA inhibited NGF mediated neuritogenesis by blocking both oncogenic ras and NGF mediated 
neuritogenesis.  However, adding TSA one hour after addition of NGF did not inhibit the NGF 
mediated neuritogenesis, suggesting that TSA affected the early gene expression in NGF-induced 
neuritogenesis by promoting histone deacetylation.  Wang et. al., (2009) reported that TSA 
treatment resulted in decreased survival and increased apoptosis in dopaminergic neuronal cells 
like N27, MN9D and human SH-SY5Y cells.  Our results show that belinostat, a p53 activator and 
an HDACi belonging to the hydroxamic acid class, did not induce neurite outgrowth in NS-1 cells 
by itself; however, intriguingly it significantly attenuated the NGF-mediated neuritogenesis when 
the cells were co-treated with belinostat and NGF.  The results suggest that belinostat might inhibit 
ras mediated neurite outgrowth induced by NGF, as reported earlier for TSA mediated inhibition 
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in neuite outgrowth in PC12 cells (Futamura et. al., 1995).  These contrasting effects of HDACi 
may be attributed to varying epigenetic status, cell type and tissue specificity.  The non-selective 
HDAC inhibition by TSA and belinostat may be contributing to contradictory effects of the 
HDACi observed in different cell types.  
The isoform specific HDACi  PCI-34051, a selective HDAC8 inhibitor, did not affect the 
viability up to 10 M concentrations and increased the neurite outgrowth in NS-1 cells at 5 μM.  
In a study with two neuroblastoma cell lines, BE (2)-C and Kelly, PCI-34051 did not affect the 
viability of the cells and did not induce the differentiation of neuroblastoma cells (Frumm et. al, 
2014).  A recent immunolocalization study reported presence of high levels of HDAC8 in the 
cytoplasm of histamine neurons with a pericellular pattern but not in other neuropeptidergic and 
monoaminergic neurons (Takase et. al, 2013).  NBM-T-L-BMX-OS01 (BMX), derived from the 
semisynthesis of osthole, isolated from Cnidium monnieri (L.) Cuss., and a potent inhibitor of 
HDAC8 has been shown to enhance neurite outgrowth and cAMP response element-binding 
protein (CREB) activation and also improved neural plasticity, learning and memory in rats ( Yang 
et. al.,2013).  
A previous study with dorsal root ganglion neurons has shown that inhibiting HDAC6 
protected against neuronal degeneration and stimulated neurite outgrowth (Rivieccio et. al., 2009).  
Tubastatin-A at 5 μM significantly increased the neurites/cells, however no increase in other end 
points was measured i.e neurite length/cell and mean neurite length in NS-1 cells at this dose or 
any other doses tested.  Co-treatment of tubastatin-A and NGF produced a significant increase in 
neurite outgrowth measured in terms of three parameters.  The neurite outgrowth in NGF and 
tubastatin-A co-treated samples was similar to the NS-1 cells treated with NGF alone.  Quinazolin-
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4-one derivatives containing a hydroxamic acid moiety, identified as selective and potent HDAC6 
inhibitors, were found to induce neurite outgrowth in PC12 and SH-SY5Y neuronal cells without 
producing toxic or mitogenic effects (Yu et. al., 2013).  Further, the analogs also caused an increase 
in acetylation of non-histone protein, -tubulin.  A Tetrahydroisoquinoline analogs, identified as 
a dual HDAC6 and HDAC8 inhibitors, produced elevated levels of acetylated tubulin, TrkA, and 
neurite outgrowth in neuroblastoma BE (2)C cells (Tang et. al., 2014). 
Contrasting reports have also been made regarding functions and role of sirtiuns, the NAD+ 
dependent HDACs in neuritic outgrowth and neuronal differentiation.  Sirtuins play important role 
in maintaining the neuronal health, especially during the conditions leading to neurodegeneration 
and aging (de Oliveira et. al., 2010; Donmez, 2012) SIRT1, a sirtuin HDAC, has been shown to 
play important role in axonal elongation, neurite outgrowth, dendritic branching and memory 
formation by modulating synaptic plasticity (Herskovits and Guarente, 2014).  Expression of 
SIRT1 has been confirmed in the cytoplasm of PC12 cells.  Activators of SIRT1 promoted the 
NGF-induced neurite outgrowth of PC12 cells, while SIRT1 inhibitors or SIRT1-siRNA 
significantly inhibited it.  The overexpression of a mutant SIRT1 that localized to the cytoplasm 
but not the nucleus enhanced the NGF-dependent neurite outgrowth, while a cytoplasmic 
dominant-negative SIRT1 suppressed it.  These experiments concluded that cytoplasmic SIRT1 
potentiated the NGF-induced neurite outgrowth of PC12 cells (Sugino et. al., 2010).  
Contrastingly, differentiation and maturation of embryonic cortical neurons and N2a 
neuroprogenitor cells was reported to be associated with decreases in SIRT1 expression (Liu et. 
al., 2014).  
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This was further confirmed by the observation that shRNA-mediated knock down of SIRT1 
resulted in induction of neurite outgrowth, whereas overexpression of SIRT1 attenuated the neural 
differentiation in N2a cells.  Tenovin-1, the SirT1 and SirT2 inhibitors, attenuated the NGF- 
stimulated neurite outgrowth in NS-1 cells confirming the role of sirtuins in neuronal 
differentiation as reported earlier. 
In conclusion, the results reported here again implicate varying responses of the HDACi 
and differential roles of different HDACs in different cell types regarding their role in 
differentiation of neuronal cells.  Among the battery of HDACi tested vorinostat was the only 
HDACi which showed the most prominent neurotrophic action.  The neurotrophic action of 
vorinostat was independent of NGF.  Other HDACi tested showed relatively marginal and variable 
effects on the neuritic outgrowth in the NS-1 cells. 
4.2. Pathways and mechanisms for neurotrophic actions of HDACi  
Neurotrophic actions enhance neuroplasticity and neurite outgrowth, which are important 
markers for neuroregeneration, neuronal differentiation and repair of neuronal injuries (Akagi et. 
al, 2015).  These processes are regulated by extrinsic and intrinsic determinants that affect gene 
expression and signal transduction pathways (Nakamura et. al., 2008).  Recent studies have 
reported neuroprotective effects of the HDACi.  The HDACs regulate expression of genes through 
deacetylation of histones and activation of transcription. The results presented here show that 
vorinostat induced neuritogenesis in NS-1 cells.  Attenuation of neurite outgrowth in presence of 
MEK1/2 inhibitor, U0126 suggests the involvement of the ERK pathway in vorinostat-induced 
differentiation of the NS-1 cells. Mitigation of ERK phosphorylation mediated by vorinostat in 
presence of U0126 further confirms the involvement of MAPK pathway.  The potential 
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involvement of the PI3K pathway was also tested.  Although neuritogenesis induced by vorinostat 
was attenuated in presence of PI3K inhibitor (LY294002).  However, the attenuation of vorinostat-
induced neuritogenesis by the PI3K inhibitor was partial and less prominent as compared to the 
ERK inhibitors, U0126 and PD98059.  Studies with inhibitors of TrkA (Tyrosine Kinase A) in 
vorinostat treated cells attenuated the neurite outgrowth and also reduced the phosphorylation of 
ERK.  This suggested role of activation of upstream kinase TrkA, the neurotrophin receptor, in the 
process of vorinostat mediated neurite outgrowth and activation of MAPK pathway.  However, 
the mechanism for activation of TrkA by vorinostat was still not clear.  Vorinostat also induced 
hyperacetylation of histones H3 and H4 in NS-1 cells, which suggested histone acetylation plays 
as important role in the induction of neurite outgrowth.  The results are in agreement with the other 
reports, where increases in acetylation of histones and transcription factors in neurons have been 
shown to promote the differentiation of neurons, whose molecular mechanisms are to some extent 
shared at some point in neurite outgrowth.  Hyperacetylation of histone H3 and H4 has been 
correlated with the plasticity of neuron and developmental process (Guab et. al., 2010).  Vorinostat 
also induced hyperacetylation of α-tubulin in NS-1 cells, hyperacetylation of α-tubulin is important 
for microtubule stabilization and transportation (Hubbert et. al., 2002).  Hyperacetylation of α-
tubulin occurs due to pharmacological inhibition of HDAC6 that leads to increased acetylation of 
α-tubulin (Zhang et.al, 2003).  HDAC class I and HDAC6 also could directly regulate neurite 
growth independently of epigenetic effects on transcription through deacetylation of α-tubulin and 
other proteins (Hubbert et. al., 2002; Rivieccio et. al., 2009). Vorinostat mediated hyperacetylation 
of α-tubulin demonstrates the importance of acetylation of tubulin in the process of neurite 
outgrowth.  Tubastatin-A also induced hyperacetylation of α-tubulin in NS-1 cells; however, its 
response in terms of neurite outgrowth was not similar to vorinostat, suggesting that other factors 
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also influence the neurite outgrowth.  Neurotrophin-mediated activation of TrkA receptor leads to 
activation of selected complex sets of signaling pathways (Patapoutian and Reichardt, 2001), 
which involve large number of signaling events associated with neurite extension/differentiation 
and neuroprotection.  These signaling pathways mainly function through phosphorylation of select 
sets of kinases.  Three major neurotrophin signaling pathways are (I) Ras/mitogen-activated 
protein kinase (MAPK) pathway, (II) Phosphatidylinositol-3 kinase pathway (PI3-K)/AKT 
pathway, and (III) Phospholipase C (PLC)- pathway (Shimoke et.al., 2009).  The MAPK cascade 
is the most implicated pathway in controlling neuritogenesis/differentiation of neuronal cells 
(Kaplan and Miller, 1997).  Ras-extracellular signal regulated kinase (RAS-ERK) pathway also 
plays important role in neuronal differentiation (Enarson et. al, 2002).  Activation of small 
GTPase, Ras through neurotrophin leads to signaling and transcription regulation, and plays an 
important role in neuronal survival and differentiation (Moodie et. al., 1993).  Activation of Ras 
leads to downstream activation of Raf1 and B-Raf, which in turn activates mitogen activated 
protein kinases MEK1 and MEK2, which further lead to phosphorylation of another set of MAP 
kinases, ERK1 and ERK2.  MEK1 and MEK2 are dual-specificity protein kinases that function in 
the mitogen activated protein kinase (MAPK) cascade.  The ERK signaling pathway controls cell 
growth, proliferation, differentiation and cell survival.  The NGF-induced neuritogenesis in PC12 
cells occurs via sustained activation of extracellular signal regulated kinase through activation of 
TrkA (Marshall 1998; Rak-hit et. al., 2001; Vaudry et. al., 2002).  NGF also activates PI3K and 
downstream effector kinase PKB/Akt, playing a role in neuronal survival.  The study was 
performed to assess the mechanism of vorinostat-induced neurite outgrowth, the activation of ERK 
pathway given its accepted role in cellular differentiation (Enarson et. al, 2002).  As vorinostat 
independently induced neuritogenesis in NS-1 cells like NGF, it is hypothesized that vorinostat-
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mediated differentiation in NS-1 cells might occur via activation of ERK and/or PI3K pathways, 
similar to the activation by NGF.  Both TrkA-associated pathways, namely MEK/MAPK and 
PI3K, were interrogated for vorinostat-induced neuritic outgrowth.  This result suggested that 
vorinostat promotes neuritogenesis in NS-1 cells via activation of the ERK pathway.  Blockade of 
vorinostat–induced differentiation measured in terms of mean neurite length, neurites/cell and 
neurite length/cell by PD98059 and U0126 indicates that activation of ERK by MEK is required 
for this effect.  Treatment of NS-1 cells with vorinostat also activated phosphorylation of ERK.  
Vorinostat mediated neuritogenesis as well as activation of ERK was attenuated by TrkA inhibitor 
suggesting the involvement of TrkA receptor in the activation of ERK pathway by vorinostat.  The 
mechanism by which vorinostat brings about differentiation and neuritogenesis in NS-1 cells may 
be through binding and activation of relevant neurotrophin receptor (Chen et. al., 2012).  However, 
other associated signaling events and the precise mechanism for activation of ERK by vorinostat 
should be examined further.  Vorinostat, as an anticancer agent in epidermal squamous cell 
carcinoma, reduced cell survival by a reduction in mTOR pathway and ERK signaling pathway 
(Deepali et. al, 2009).  However, in a different study, vorinostat treatment in lymphoplasmacytic 
cells in waldenstrom macroglobulinemia led to apoptosis by affecting MAPK pathways (Jenny et. 
al, 2011). The phospho-extracellular signal regulated kinase was abruptly decreased at 24 hours, 
while phospho 38 MAPK was up regulated at 12 hours in Lymphoplasmacytic cells (Jenny et. al., 
2011). These reports indicate that the MAPK/ERK pathways show varying response to vorinostat 
depending on the target cells.   
The Valproic acid (VPA), an HDACi used as an anticonvulsant and mood-stabilizing drug 
for treatment of epilepsy, bipolar disorder and prevention of migraine headaches, has been shown 
to be neuroprotective in primary astroglial cultures. VPA induced the expression of GDNF and 
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BDNF, which in turn activated the ERK pathway in primary astroglial cultures (Chen et. al., 2006). 
Yuan et. al., (2001) reported that VPA stimulated neurite outgrowth in SH-SY5Y cell culture by 
activation of ERK pathway. These actions of VPA were similar to the effects exerted by the 
neurotrophic factors.  The neurotrophic and neuroprotective effect of VPA, such as neuronal 
survival, neurite outgrowth and neurogenesis involve multiple mechanisms.  VPA is also known 
to modulate the activity of several intracellular enzymes, including mitogen-activated protein 
kinases (MAPKs), protein kinase C (PKC) and glycogen synthase kinase-3β (GSK-3β) 
(Kostrouchova et.al, 2007). Apart from HDAC inhibition and histone hyperacetylation, activation 
of ERK pathway (Hao et. al., 2004; Yuan et. al., 2001), microglial–mediated inflammation (Peng 
et. al., 2005) and inhibition of pro-apoptotic factors (Kim et. al., 2007) have also been reported 
earlier for VPA.  The results presented support the hypothesis that neurotrophic activity of 
vorinostat is mediated through activation of ERK pathway, histone hyperacetylation and 
acetylation of non–histone proteins like α-tubulin. HDACi have shown significant impacts on 
neuronal, cardiomyocytic, and hepatic lineage differentiations.  In most of the cases molecular 
mechanism for induction of differentiation have been linked to regulation of transcription factors 
(Gaub et. al., 2010).  In experimental models of disease such as, amylotrophic lateral sclerosis, 
multiple sclerosis and Huntington’s disease, neuroprotective effects of HDACi have been noted. 
However, precise mechanisms for their neuroprotection action are still obscure. Activation of the 
ERK pathway via TrkA receptor seems to be one of the mechanisms for induction of 
neuritogenesis by vorinostat in NS-1 cells.  In contrast to the more rapid induction of ERK 
phosphorylation by NGF, vorinostat-induced phosphorylation of ERK was delayed, and was 
relatively transient and more stable.  These observations imply that vorinostat may be readily 
inactivated, or perhaps the mechanism of ERK activation by vorinostat is different from that of 
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NGF.  Vorinostat-induced neurite outgrowth appears to involve not only MEK, but also PI3K, 
since the neuritogenesis was inhibited in presence of LY294002, a PI3K inhibitor.  As the 
differentiation of cells is typically associated with a cell cycle arrest, we also analyzed the effects 
of vorinostat on cell cycle of NS-1 cells.  The flow cytometer analysis results for cell cycle studies 
in vorinostat and NGF treated NS-1 cells showed significant decline in percentage of cells in S 
phase at 24 and 48 hours post treatment, suggesting that the major population of cells were arrested 
in differentiation stage.  Neuroendocrine cells have been shown to differentiate in presence of 
ligands that activate G protein coupled receptors, which in turn increase the level of cAMP.  
Previous reports have also suggested important role of cAMP in NGF-mediated neuritogenesis. 
Chen et. al., (2010) have shown, using molecular pathway inhibitors, that cAMP played a role in 
activation of p35/Cdk5 and this regulation was an important pathway for NGF-mediated 
differentiation of PC12 cells.  A recent contrasting report by Emery et. al., (2014) showed that 
NGF-mediated differentiation of PC12 and NS-1 cells did not require cAMP sensors protein kinase 
A, Epac, or neuritogenic cyclic AMP sensor/Rapgef2.  The NGF-mediated signaling rather 
involved ERK and p38 activation through a cAMP independent pathway.  The cAMP cascade has 
also been shown to have as important role in neuronal survival, plasticity, and differentiation 
(Nakagawa et. al, 2002).  It is also investigated the involvement of cAMP pathway in vorinostat 
mediated neurite outgrowth.  Surprisingly, adenlyate cyclase inhibitor SQ22536 further 
potentiated the neurite outgrowth induced by vorinostat.  These results suggested that the signaling 
pathway(s) for vorinostat mediated neuritogenesis may be different from NGF-mediated signaling 
mechanisms as NGF-mediated neurite outgrowth was not affected in presence of adenylate cyclase 
inhibitor SQ22536.  It would be important to investigate the possible role of other converging 
kinases, such as the cAMP and PKA-dependent pathway, in the downstream neuritogenic 
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pathways or the pathways independent of MAPK/ERK activation.  It would also be interesting to 
assess transcription dependent effect of vorinostat on NS-1 cell differentiation and regulation of 
expression of genes linked to the pathways of neuronal differentiation, neuritogenesis and 
neuroprotection.  This study establishes neurotrophic potential of vorinostat, and partly elucidates 
cellular and molecular mechanisms for vorinostat-mediated neurite outgrowth in NS-1 cells.  
Vorinostat induced neuritogenesis appears to involve activation of ERK pathways through TrkA 
receptor.  Vorinostat induces hyperacetylation of α-tubulin which plays important role in 
neuriteoutgrowth /differentiation process.  Hyperacetylation of histones H3 and H4 by vorinostat 
in NS-1 cells suggest significant role of transcription regulation of genes related to differentiation. 
Vorinostat is permeable to the blood brain barrier (Grant 2007; Lemonie& Younes, 2010), which 
makes it an important drug candidate for targeting central nervous system.  Vorinostat and other 
related HDACi with neurotrophic actions may be evaluated as promising candidates and potential 
therapeutic agents for treatment of neurodegenerative diseases and neuronal injuries by virtue of 
their ability to stimulate neuritic outgrowth. 
Belinostat, also a pan HDACi, shows a completely different response in terms of neurite 
outgrowth as compared to vorinostat in NS-1 cells.  Belinostat did not induce neurite outgrowth 
by itself and it attenuated the neurite outgrowth induced by NGF.  Belinostat did not induce ERK 
phosphorylation by itself however, but it further increased the phosphorylation of ERK in presence 
of NGF.  These results suggest that other factors may be involved in attenuation neurotrophic 
action of NGF by belinostat.  Belinostat (0.5M) induced hyperacetylation of histones H3 and H4 
similar to that by vorinostat.  
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Tenovin-1, a sirtunin (SirT1 and SirT2) inhibitor, also inhibited NGF-mediated neurite 
outgrowth.  Tenovin-1 did not affect phosphorylation of ERK dependently and also did not induce 
hyperacetylation of histones H3 and H4.  
Vorinostat and tubastatin-A both caused hyperacetylation of α-tubulin in NS-1 cells. 
However, their response in terms of neurite outgrowth was different.  Vorinostat significantly 
induced neurite outgrowth in all the three parameters tested, but tubastain-A induced neurites/cell 
but not neurite length/cell or mean neurite length.  Tubastatin-A is a selective HDAC6 inhibitor 
and vorinostat also inhibits HDAC6.  This suggests that additional on-target as well as off-target 
effects of HDACi other than inhibition of HDAC6 may be important in the process of 
neuritogenesis. 
To the best of our knowledge, this is the first study showing role of the ERK pathway and 
upstream kinase TrkA in Vorinostat-induced neurite outgrowth in NS-1 cells.  This finding is in 
agreement with a number of previous studies, which have shown that HDACi exert 
neuroprotective & neuritogenic effects via activation ERK pathways (Hao et. al., 2004; Hsieh et. 
al., 2004).  Treatment of NS-1 cells with vorinostat and inhibitors of adenylate cyclase increased 
the neurite outgrowth in NS-1 cells suggesting the role of other pathways and factors in inducing 
vorinostat mediated differentiation of NS-1.  
These observations imply that differentiation is a process that occurs through the 
simultaneous activation of multiple parallel signaling events rather than a single master pathway 
(Ravni et. al., 2008).  It would be important to investigate the possible role of other converging 
kinases, such as the cAMP and PKA-dependent pathway in detail, in the downstream neuritogenic 
pathways or the pathways independent of MAPK/ERK activation.  It would also be interesting to 
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assess transcription dependent effect of Vorinostat on NS-1 cell differentiation and regulation of 
expression of genes linked to the pathways of neuronal differentiation, neuritogenesis and 
neuroprotection.  
This study demonstrates a neurotrophic effect of vorinostat, and elucidates cellular and 
molecular mechanisms for Vorinostat-mediated neurite outgrowth in NS-1 cells.  Vorinostat 
induced neuritogenesis appears to involve activation of ERK pathways through activation of TrkA 
receptor.  Vorinostat also induces hyperacetylation of α-tubulin which plays important role in 
neurite outgrowth /differentiation process.  Hyperacetylation of histones H3 and H4 by vorinostat 
in NS-1 cells suggest significant role of transcription regulation of genes related to differentiation.  
Vorinostat is permeable to the blood brain barrier (Grant, 2007; Lemonie&Younes, 2010), which 
makes it an important drug candidate for targeting central nervous system.  Other pan, selective 
and isoform specific HDACi tested had variable results in terms of neurite outgrowth in NS-1 
cells.  Detailed study of these inhibitors vis-à-vis their mechanism of actions are required to 
ascertain the role of each HDAC inhibitors in the process of differentiation and to know what 
causes the variable response of  HDACi in NS-1 cells.  
Vorinostat and other related HDACi with neurotrophic actions could be a promising 
candidates and potential therapeutic agents for treatment of neurodegenerative diseases and 
neuronal injuries by virtue of their ability to stimulate neuritic outgrowth.  
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SUMMARY AND CONCLUSION 
The neurodegenerative disease like Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease and Amyotrophic lateral sclerosis are primarily characterized by progressive 
loss and death of neurons due to their diminished structure and functions.  Progressive 
neurodegeneration occurs as a part of normal aging process.  The traumatic brain and spinal cord 
nerve injuries also cause loss of functions of neurons.  The drugs capable of stimulating 
neuroregeneration and induction of neuritic growth may reverse the loss of neuronal functions due 
to neurodegenerative diseases and nerve injuries.  Neurite outgrowth is a fundamental process in 
differentiation of neurons, which plays a critical role in formation of new neurons, remodeling of 
synapse, repair of damaged neurons and regeneration of neurons.  The neurotrophic factors, 
commonly referred as neurotrophins are proteinaceous factors, which are important for survival, 
maintenance and development of central and peripheral nervous systems.  Preclinical studies point 
to the therapeutic potential of neurotrophic factors in preventing or slowing the progression of 
neurodegenerative conditions by repair and restoration of normal neuronal function of the 
damaged neurons.  However, owing to the inherent difficulties with a protein therapeutic approach 
for treating central nervous system disorders, increasing attention has turned to the development 
of alternative strategies and, in particular, small molecule mimetic.  The inhibitors of histone 
deacetylases (HDAC) being small molecule inhibitors and many of them having ability to cross 
the blood brain barrier offer important leads for their evaluation as potential neurotrophic agents. 
HDACs are the components of process of reversible acetylation/deacetylation of histones and 
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several non-histone proteins and are known to play important role in transcriptional regulation and 
gene expression.  Reports have indicated important role of HDACi in the process of neurite 
outgrowth, neuronal differentiation and neuroprotection.  Therefore, the HDACi may be the 
potential drug leads for treatment of neurodegenerative diseases.  In view of this, a battery of 
HDACi were evaluated as potential neurotrophins.  The lead HDACi with promising neurotrophic 
action was further evaluated to understand the mechanism of their action.     
Evaluation of HDACi as potential neurotrophic agents and understanding the mechanism of 
their actions 
Eleven isoforms of HDACs have been broadly divided into three classes based on their 
sequence homology and comparative domain structures.  Another unrelated class of HDACs, 
referred as sirtiuns, contains additional 7 isoforms.  A set of pan and isoform specific HDACi were 
selected and evaluated in vitro on NeuroScreen-1 (NS-1) cell line, which is a clone of PC12 cells 
derived from a pheochromocytoma of the rat adrenal medulla.  The PC12 cells, when treated with 
nerve growth factor (NGF), an indigenous neurotrophin, induces neurite outgrowth and creates the 
cells with morphology like growing neurons.  This model has been used extensively for 
understanding the mechanisms of neurotrophin actions, neuritogenesis and neurosecretion.  
A combined in vitro method was standardized with NS-1 cells that measures and quantifies 
neurite outgrowth along with the cell viability (cytotoxicity of the test compounds) in a single 
assay.  The stimulation of neurite outgrowth was measured by analysis of digital cell images by 
the NIS software in terms of multiple parameters namely, the effect of test compounds on mean 
neurite length, neurite length/cell, nodes/cell and number of neurites/cells. 
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Out of the several HDAC inhibitors tested for their effects on neurite outgrowth in NS-1 
cells, vorinostat, a pan HDAC inhibitor, significantly induced neurite outgrowth.  The independent 
neurotrophic action of vorinostat was similar to that induced by NGF.  Vorinostat is currently 
under clinical use for treatment of cutaneous T cell lymphoma (CTCL).  The inhibitors of 
neurotrophin molecular signaling pathway namely U0126, PD98059 (the inhibitors of MAP 
kinases MEK1/MEK2) and LY294002 (the PI3K inhibitor) were employed to understand the 
mechanism for neurotrophic actions of vorinostat.  These inhibitors significantly attenuated the 
vorinostat mediated neurite outgrowth in NS-1 cells, and also reduced the level of ERK 
phosphorylation.  These results implicated that vorinostat induced neuritogenesis occurs through 
activation of ERK and PI3K signaling pathways, which is similar to that reported for NGF.  The 
role of upstream neurotrophin receptor kinase TrkA was also studied in vorinostat induced neurite 
outgrowth using a TrkA inhibitor, GW441756.  The vorinostat mediated neurite outgrowth was 
reduced in presence of TrkA inhibitor. GW441756 also abolished vorinostat mediated ERK 
phosphorylation/activation, suggesting the role of upstream kinase TrkA in the vorinostat mediated 
neurite outgrowth and activation of ERK. 
The neurotrophin signaling has been shown to involve cAMP downstream in the pathways.  
SQ22536, a selective inhibitor of adenylate cyclase, was tested on vorinostat-induced neurite 
outgrowth in NS-1 cells.  Intriguingly, SQ22536 potentiated the vorinostat induced neurite 
outgrowth suggesting the possible role of additional signaling pathways in neurotrophic action of 
vorinostat.  Stimulation of vorinostat mediated neuritogenesis may not be solely attributed to the 
activation of TrkA/MAPK/PI-3K pathway and would require interrogation of additional signaling 
pathways.  
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Treatment of NS-1 cells with vorinostat and flow cytometric analysis showed that the drug 
arrested the cells in G2M phase, as indicated by decrease in cells in S phase with concomitant 
increase of cells in G2M phase.  Further, vorinostat treatment resulted in hyperacetylation of 
histones (H3 & H4) and α-tubulin as indicated by Western blot analysis of NS-1 cells lysates and 
immunostaining of the treated cells with anti-α-tubulin antibodies. 
Other pan-HDAC inhibitors namely trichostatin-A (TSA) and belinostat showed different 
responses on the NS-1 cells, compared to prominent neurotrophic action of vorinostat. TSA is an 
antifungal antibiotic and selective inhibitor of class I and II HDACs.  Treatment of NS-1 cells with 
TSA did not induce neurite outgrowth.  Also, TSA treatment did not show significant effect on 
neurotrophic action of NGF.  Belinostat (referred as PDX101) also is a potent inhibitor of class I 
and II HDACs and presently under development for treatment of hematological malignancies.   
Similar to TSA, belinostat also did not induce neurite outgrowth in NS- 1 cells by itself.  However 
it significantly attenuated the NGF-mediated neurite outgrowth in NS-1 cells.  Belinostat by itself 
did not induce phosphorylation of ERK.  However, there was increased phosphorylation of ERK 
in NS- cells co-treated with belinostat and NGF.  The increase in phosphorylation of ERK in NS-
1 cells treated with belinostat and NGF compared to the NS-1 cells treated with NGF alone 
contrasted the observation regarding attenuation of NGF-mediated neurite outgrowth belinostat 
and would required additional investigations.  Treatment of NS-1 cells with belinostat induced 
hyperacetylation of histones H3 and H4.  However, it did not induce the hyperacetylation of α-
tubulin like vorinostat. 
PCI-34051, a HDAC 8 inhibitor was also evaluated for potential neurotrophic action and 
induction of neurite outgrowth in NS-1 cell.  Treatment of NS-1 cells with PCI-34051 induced the 
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neurite outgrowth. However, treatment of NS-1 cells with PCI-34051 did not produce 
hyperacetylation of histones (H3 and H4) and α-tubulin.  The observations indicate a differential 
mechanism for neurotrophic action of PCI-34051.  
Treatment of NS-1 cells with tubastatin-A, a selective HDAC6 inhibitor, produced 
significant hyperacetylation of α-tubulin.  However, tubastatin-A neither produced significant 
effect on the neurite outgrowth alone nor it have any effect on NGF-stimulated neurite outgrowth. 
Tenovin-1 a sirtunin SirT1 and SirT2 inhibitor, did not induce neurite outgrowth by itself. 
However, it significantly attenuated the neurite outgrowth induced by NGF, similar to that 
observed with belinostat.  Tenovin did not show acetylation of histone H3/H4 in NS-1 cells. 
Earlier, it has been reported to cause hyperacetylation of histone H4 and activate p53.  
The results presented regarding neurotrophic action of different HDAC inhibitors indicate 
multiple mechanisms of their actions. The vorinostat mediated neurotrophic response shows 
involvement of conventional neurotrophin signaling pathways such as activation of extracellular 
neurotrophin receptor TrkA and subsequent activation of ERK/PI-3K pathways.  
Differential epigenetic status of the NS-1 cells at the time of treatment with these HDAC 
inhibitors as well as expression of a select set of gene during the process of neurite out growth/ 
differentiation might be attributed to the varying response of the HDAC inhibitors.  It may be 
interesting to assess the transcription dependent/independent effects of the individual HDAC 
inhibitors in NS-1 cells and monitor specific gene expression changes during the process of 
differentiation of the NS-1 cells. .  
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In conclusion, the results presented clearly established vorinostat to induce neurite 
outgrowth in NS-1 cells.  These studies have advanced our knowledge and understanding 
regarding mechanism action of vorinostat in promoting neuritogenesis and neuronal 
differentiation.  These studies also suggested that the HDAC inhibitor like vorinostat may be of 
significant interest in the development of novel therapeutic approaches for treatment of 
neurodegenerative diseases by virtue of their ability to induce neurite outgrowth and their ability 
to cross blood brain barrier.  Additionally these studies have also shed light on other pan and 
selective HDAC inhibitors regarding their potential to induce neurite outgrowth in NS-1 cells and 
also partially elucidated their mechanism for action. 
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